1
|
Mannarino S, Lanna M, Calcaterra V, Carzaniga T, Casiraghi L, Lai A, Gabrieli A, Bergna A, Fini G, Bianchi S, De Amici M, Zehender G, Bellini T, Buscaglia M, Zuccotti G. Fetal Myocarditis Associated With Maternal SARS-CoV-2 Infection. Pediatr Infect Dis J 2024; 43:454-456. [PMID: 38190639 DOI: 10.1097/inf.0000000000004245] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/10/2024]
Abstract
We report the first case of significant fetal myocardial involvement associated with maternal SARS-CoV-2 infection, in which restoration of cardiac function at birth was noted. The demonstration of previous infection was supported by the quantification of humoral response in child and mother, in particular the presence of anti-N antibodies and through the detection of specific antibodies against the BA.4/5 variant.
Collapse
Affiliation(s)
- Savina Mannarino
- From the Pediatric Cardiology Unit, Buzzi Children's Hospital, Milan, Italy
| | - Mariano Lanna
- Fetal Therapy Unit "U. Nicolini"
- Department of Women, Mother and Neonate, Buzzi Children's Hospital, University of Milan, Milan, Italy
| | - Valeria Calcaterra
- Department of Internal Medicine, University of Pavia, Pavia, Italy
- Pediatric Department, Buzzi Children's Hospital, Milan, Italy
| | - Thomas Carzaniga
- Department of Medical Biotechnology and Translational Medicine, University of Milan, Segrate, Italy
| | - Luca Casiraghi
- Department of Medical Biotechnology and Translational Medicine, University of Milan, Segrate, Italy
| | - Alessia Lai
- Department of Biomedical and Clinical Science, University of Milan, Milan, Italy
| | - Arianna Gabrieli
- Department of Biomedical and Clinical Science, University of Milan, Milan, Italy
| | - Annalisa Bergna
- Department of Biomedical and Clinical Science, University of Milan, Milan, Italy
| | - Giulia Fini
- From the Pediatric Cardiology Unit, Buzzi Children's Hospital, Milan, Italy
| | - Silvia Bianchi
- Division of Neonatology, Buzzi Children's Hospital, Milan, Italy
| | - Mara De Amici
- Immuno-Allergology Laboratory, Clinical Chemistry Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | | | - Tommaso Bellini
- Department of Medical Biotechnology and Translational Medicine, University of Milan, Segrate, Italy
| | - Marco Buscaglia
- Department of Medical Biotechnology and Translational Medicine, University of Milan, Segrate, Italy
| | - Gianvincenzo Zuccotti
- Pediatric Department, Buzzi Children's Hospital, Milan, Italy
- Department of Biomedical and Clinical Science, University of Milan, Milan, Italy
| |
Collapse
|
2
|
Dalu D, Tarkowski M, Ruggieri L, Cona MS, Gabrieli A, De Francesco D, Fasola C, Ferrario S, Gambaro A, Masedu E, Parma G, Rulli E, De Stradis C, Mavilio D, Calcaterra F, Manoni F, Riva A, La Verde N. Antibody response to three-dose anti-SARS-CoV-2 mRNA-vaccination in treated solid cancer patients. Int J Cancer 2024; 154:1371-1376. [PMID: 38100252 DOI: 10.1002/ijc.34817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2023] [Revised: 11/01/2023] [Accepted: 11/06/2023] [Indexed: 12/17/2023]
Abstract
Solid cancer patients are at higher risk of SARS-CoV-2 infection and severe complications. Moreover, vaccine-induced antibody response is impaired in patients on anticancer treatment. In this retrospective, observational, hypothesis-generating, cohort study, we assessed the antibody response to the third dose of mRNA vaccine in a convenience sample of patients on anticancer treatment, comparing it to that of the primary two-dose cycle. Among 99 patients included, 62.6% were ≥60 years old, 32.3% males, 67.7% with advanced disease. Exactly 40.4% were receiving biological therapy, 16.2% chemotherapy only and 7.1% both treatments. After the third dose, seroconversion rate seems to increase significantly, especially in non-responders to two doses. Heterologous vaccine-type regimen (two-dose mRNA-1273 and subsequent tozinameran or vice versa) results in higher antibody levels. This explorative study suggests that repeated doses of mRNA-vaccines could be associated with a better antibody response in this population. Furthermore, heterologous vaccine-type three-dose vaccination seems more effective in this population. Since this is a hypothesis-generating study, adequately statistically powered studies should validate these results.
Collapse
Affiliation(s)
- Davide Dalu
- Department of Medical Oncology, Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Maciej Tarkowski
- Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Milan, Italy
| | - Lorenzo Ruggieri
- Department of Medical Oncology, Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Maria Silvia Cona
- Department of Medical Oncology, Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Arianna Gabrieli
- Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Milan, Italy
| | - Davide De Francesco
- Department of Biomedical Data Sciences, Stanford University, Stanford, California, USA
| | - Cinzia Fasola
- Department of Medical Oncology, Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Sabrina Ferrario
- Department of Medical Oncology, Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Anna Gambaro
- Department of Medical Oncology, Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Elsa Masedu
- School of Medicine, "Polo Universitario Luigi Sacco", University of Milan, Milan, Italy
| | - Gaia Parma
- School of Medicine, "Polo Universitario Luigi Sacco", University of Milan, Milan, Italy
| | - Eliana Rulli
- Laboratory of Methodology for Clinical Research, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - Claudia De Stradis
- Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Milan, Italy
| | - Domenico Mavilio
- Unit of Clinical and Experimental Immunology, IRCCS Humanitas Research Hospital, Milan, Italy
- Department of Medical Biotechnologies and Translational Medicine (BioMeTra), University of Milan, Milan, Italy
| | - Francesca Calcaterra
- Unit of Clinical and Experimental Immunology, IRCCS Humanitas Research Hospital, Milan, Italy
- Department of Medical Biotechnologies and Translational Medicine (BioMeTra), University of Milan, Milan, Italy
| | - Federica Manoni
- Department of Medical Oncology, Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Agostino Riva
- Department of Infectious Diseases, Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Nicla La Verde
- Department of Medical Oncology, Luigi Sacco University Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| |
Collapse
|
3
|
Colaneri M, Scaglione G, Fassio F, Galli L, Lai A, Bergna A, Gabrieli A, Tarkowski M, Ventura CD, Colombo V, Cordier L, Bernasconi D, Corbellino M, Dedivitiis G, Borghetti S, Visigalli D, Sollima S, Casalini G, Rizzardini G, Gori A, Antinori S, Riva A, Schiavini M. Early administration of nirmatrelvir/ritonavir leads to faster negative SARS-CoV-2 nasal swabs than monoclonal antibodies in COVID 19 patients at high-risk for severe disease. Virol J 2024; 21:68. [PMID: 38509536 PMCID: PMC10953281 DOI: 10.1186/s12985-024-02333-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2023] [Accepted: 02/28/2024] [Indexed: 03/22/2024] Open
Abstract
PURPOSE Besides the well-established efficacy in preventing severe COVID-19, the impact of early treatments, namely antivirals and monoclonal antibodies (mAbs), on the time length to negativization of SARS-CoV-2 nasal swabs is still unclear. The aim of this study was to compare the efficacy of different early treatments in reducing the SARS-CoV-2 viral shedding, identifying a single drug that might potentially lead to a more rapid negativization of SARS-CoV-2 nasal swab. METHODS This was a single-centre, retrospective, observational study conducted at Ospedale Luigi Sacco in Milan. Data of high-risk COVID-19 patients who received early treatments between 23 December 2021 and March 2023 were extracted. The comparison across treatments was conducted using the Kruskall-Wallis test for continuous variables. Dunn's test with Bonferroni adjustment was performed for post-hoc comparisons of days to negativization. Secondly, a negative binomial regression adjusted for age, sex, number of comorbidities, immunosuppression, and SARS-CoV-2 vaccination status was implemented. RESULTS Data from 428 patients receiving early treatments were collected. The majority were treated with Nirmatrelvir/Ritonavir and were affected by SARS-CoV-2 Omicron infection with BA.2 sublineage. The median length time to SARS-CoV-2 nasal swab negativization was 9 days [IQR 7-13 days]. We found that Nirmatrelvir/Ritonavir determined a significant decrease of the length time to SARS-CoV-2 nasal swab negativization compared to mAbs (p = 0.003), but not compared to Remdesivir (p = 0.147) and Molnupiravir (p = 0.156). CONCLUSION Our findings highlight the importance of promptly treating high-risk COVID-19 patients with Nirmatrelvir/Ritonavir, as it also contributes to achieving a faster time to negative SARS-CoV-2 nasal swabs.
Collapse
Affiliation(s)
- Marta Colaneri
- Department of Infectious Diseases, Unit II, L. Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
- Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy
| | - Giovanni Scaglione
- Department of Infectious Diseases, Unit II, L. Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Federico Fassio
- Department of Public Health, Experimental and Forensic Medicine, Unit of Biostatistics and Clinical Epidemiology, University of Pavia, Pavia, Italy
| | - Lucia Galli
- Department of Infectious Diseases, Unit II, L. Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Alessia Lai
- Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
| | - Annalisa Bergna
- Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
| | - Arianna Gabrieli
- Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
| | - Maciej Tarkowski
- Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
| | - Carla Della Ventura
- Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
| | - Valeria Colombo
- Department of Infectious Diseases, Unit I, L. Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Laura Cordier
- Department of Infectious Diseases, Unit II, L. Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Davide Bernasconi
- Department of Infectious Diseases, Unit II, L. Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Mario Corbellino
- Institute of Infectious Diseases & Tropical Medicine, III Division, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy
| | - Gianfranco Dedivitiis
- Department of Infectious Diseases, Unit II, L. Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Silvia Borghetti
- Pharmacy Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy
| | - Debora Visigalli
- Pharmacy Unit, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy
| | - Salvatore Sollima
- Institute of Infectious Diseases & Tropical Medicine, III Division, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy
| | - Giacomo Casalini
- Institute of Infectious Diseases & Tropical Medicine, III Division, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy
| | - Giuliano Rizzardini
- Department of Infectious Diseases, Unit I, L. Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Andrea Gori
- Department of Infectious Diseases, Unit II, L. Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
- Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
- Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy
| | - Spinello Antinori
- Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
- Institute of Infectious Diseases & Tropical Medicine, III Division, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy
| | - Agostino Riva
- Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
- Institute of Infectious Diseases & Tropical Medicine, III Division, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy
| | - Monica Schiavini
- Department of Infectious Diseases, Unit II, L. Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy.
| |
Collapse
|
4
|
Bruzzesi E, Gabrieli A, Bernasconi D, Marchetti G, Calcagno A, Ripamonti D, Antinori A, Squillace N, Cingolani A, Muscatello A, Bandera A, Gori A, Rusconi S, Nozza S. HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial. J Med Virol 2023; 95:e29114. [PMID: 37752816 DOI: 10.1002/jmv.29114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Revised: 09/06/2023] [Accepted: 09/10/2023] [Indexed: 09/28/2023]
Abstract
As the introduction of antiretroviral therapy (ART) during primary HIV-1 infection (PHI) could restrict the establishment of HIV reservoirs, we aimed to assess the effect of three different ART regimens on HIV-DNA load in people living with HIV (PLWH), who started ART in PHI. Randomized, open-label, multicentric study, including subjects in PHI (defined as an incomplete HIV-1 Western blot and detectable plasma HIV-RNA) in the Italian Network of Acute HIV Infection cohort. Participants were randomly assigned (10:10:8) to a fixed-dose combination of tenofovir alafenamide fumarate (TAF) 10 mg plus emtricitabine (FTC) 200 mg, darunavir 800 mg, and cobicistat 150 mg once daily (group A), or TAF 25 mg plus FTC 200 mg, dolutegravir 50 mg once daily (group B), or an intensified four-drug regimen (TAF 10 mg plus FTC 200 mg, dolutegravir 50 mg, darunavir 800 mg, and cobicistat 150 mg once daily) (group C). The primary endpoint was the decrease of HIV-DNA copies/106 peripheral blood mononuclear cells (PBMCs) at weeks (W) 12 and 48. Secondary endpoints were increased in CD4+ cells and in CD4+/CD8+ ratio and percentage of PLWH reaching undetectable HIV-RNA. HIV-DNA was quantified by Droplet Digital PCR (Biorad QX100) and normalized to RPP30 reference gene. This study was registered in ClinicalTrials.gov (number NCT04225325). Among 78 participants enrolled, 30 were randomized to group 1, 28 to group 2, and 20 to group 3. At baseline, median CD4+ count was 658/µL (476-790), HIV-RNA 5.37 (4.38, 6.12) log10 copies/mL, without statistical difference in their change among groups at weeks 12 and 48 (p = 0.432 and 0.234, respectively). The trial was prematurely discontinued for slow accrual and for COVID-19 pandemic-associated restrictions. In the per-protocol analysis, PLWH (n = 72) with undetectable viral load was 54.3% at W12 and 86.4% at W48. Interestingly, the CD4/CD8 ratio progressively increased over time, up to normalization in almost half of the cohort by week 48, despite a deflection in group 3; no difference was observed by the Fiebig stage (I-III vs. IV-VI). HIV-DNA decreased from 4.46 (4.08, 4.81) log10 copies/106 PBMCs to 4.22 (3.79, 4.49) at week 12, and 3.87 (3.46, 4.34) at week 48, without difference among groups. At multivariable analysis, HIV-DNA delta at W48 was associated only with the increase of CD4+ count by 100 cells/mm3 but not with the Fiebig stage, the CD4+/CD8+ ratio, and treatment arm, despite a higher decrease in group 3. Six adverse events were recorded during our study, which did not cause any withdrawal from the study. We observed a decrease in HIV-DNA from baseline to W48 in PLWH treated during PHI, associated with an increase in CD4+ count, unrelated to the treatment arm.
Collapse
Affiliation(s)
| | - Arianna Gabrieli
- Dipartimento di Scienze Biomediche e Cliniche (DIBIC), Milan, Italy
| | - Davide Bernasconi
- Bicocca Bioinformatics Biostatistics and Bioimaging Centre - B4 School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
| | - Giulia Marchetti
- Clinic of Infectious Diseases, Department of Health Sciences, ASST Santi Paolo e Carlo, University of Milan, Milan, Italy
- School of Medicine and Surgery, University of Milan, Milan, Italy
| | - Andrea Calcagno
- Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy
| | - Diego Ripamonti
- Infectious Disease Unit, ASST Papa Giovanni XXIII, Bergamo, Italy
| | - Andrea Antinori
- National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy
| | - Nicola Squillace
- Infectious Disease Unit, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy
| | - Antonella Cingolani
- Istituto Clinica di Malattie Infettive, Università Cattolica del Sacro Cuore, Rome, Italy
- UOC Malattie Infettive, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
| | - Antonio Muscatello
- Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan
| | - Alessandra Bandera
- School of Medicine and Surgery, University of Milan, Milan, Italy
- Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan
| | - Andrea Gori
- School of Medicine and Surgery, University of Milan, Milan, Italy
| | - Stefano Rusconi
- School of Medicine and Surgery, University of Milan, Milan, Italy
- SC Malattie Infettive, Ospedale di Legnano, ASST Ovest Milanese, Legnano, Italy
| | - Silvia Nozza
- Vita-Salute San Raffaele University, Milan, Italy
- Infectious Diseases Unit, IRCCS Ospedale San Raffaele, Milan, Italy
| |
Collapse
|
5
|
Cona MS, Riva A, Dalu D, Gabrieli A, Fasola C, Lipari G, Pozza G, Rulli E, Galli F, Ruggieri L, Masedu E, Parma G, Chizzoniti D, Gambaro A, Ferrario S, Antista M, De Monte M, Tarkowski MS, La Verde N. Clinical efficacy of the first two doses of anti-SARS-CoV-2 mRNA vaccines in solid cancer patients. Cancer Med 2023. [PMID: 37114577 DOI: 10.1002/cam4.5968] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2022] [Revised: 03/30/2023] [Accepted: 04/06/2023] [Indexed: 04/29/2023] Open
Abstract
INTRODUCTION Cancer patients are frail individuals, thus the prevention of SARS-CoV-2 infection is essential. To date, vaccination is the most effective tool to prevent COVID-19. In a previous study, we evaluated the immunogenicity of two doses of mRNA-based vaccines (BNT162b2 or mRNA-1273) in solid cancer patients. We found that seroconversion rate in cancer patients without a previous exposure to SARS-CoV-2 was lower than in healthy controls (66.7% vs. 95%, p = 0.0020). The present study aimed to evaluate the clinical efficacy of the vaccination in the same population. METHODS This is a single-institution, prospective observational study. Data were collected through a predefined questionnaire through phone call in the period between the second and third vaccine dose. The primary objective was to describe the clinical efficacy of the vaccination, defined as the percentage of vaccinated subjects who did not develop symptomatic COVID-19 within 6 months after the second dose. The secondary objective was to describe the clinical features of patients who developed COVID-19. RESULTS From January to June 2021, 195 cancer patients were enrolled. Considering that 7 (3.59%) patients tested positive for SARS-CoV-2 and 5 developed symptomatic disease, the clinical efficacy of the vaccination was 97.4%. COVID-19 disease in most patients was mild and managed at home; only one hospitalization was recorded and no patient required hospitalization in the intensive care unit. DISCUSSION Our study suggests that increasing vaccination coverage, including booster doses, could improve the prevention of infection, hospitalization, serious illness, and death in the frail population of cancer patients.
Collapse
Affiliation(s)
- Maria Silvia Cona
- Department of Oncology, Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Agostino Riva
- Department of Infectious Diseases, Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
- Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Milan, Italy
| | - Davide Dalu
- Department of Oncology, Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Arianna Gabrieli
- Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Milan, Italy
| | - Cinzia Fasola
- Department of Oncology, Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Giuseppe Lipari
- Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Milan, Italy
| | - Giacomo Pozza
- Department of Infectious Diseases, Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Eliana Rulli
- Laboratory of Methodology for Clinical Research, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - Francesca Galli
- Laboratory of Methodology for Clinical Research, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
| | - Lorenzo Ruggieri
- Department of Oncology, Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Elsa Masedu
- Department of Oncology, Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Gaia Parma
- Department of Oncology, Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Davide Chizzoniti
- Department of Oncology, Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Anna Gambaro
- Department of Oncology, Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Sabrina Ferrario
- Department of Oncology, Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Maria Antista
- Department of Oncology, Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Matteo De Monte
- Department of Oncology, Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Maciej S Tarkowski
- Luigi Sacco Department of Biomedical and Clinical Sciences DIBIC, University of Milan, Milan, Italy
| | - Nicla La Verde
- Department of Oncology, Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| |
Collapse
|
6
|
La Verde N, Riva A, Cona MS, Gabrieli A, Cattaneo M, Fasola C, Lipari G, De Stradis C, Favorito V, Lombardi Stocchetti B, Chizzoniti D, Covizzi A, Rulli E, Galli F, Ruggieri L, Gambaro A, Ferrario S, Dalu D, Tarkowski MS. Immunogenicity of two doses of BNT162b2 and mRNA-1273 vaccines for solid cancer patients on treatment with or without a previous SARS-CoV-2 infection. Int J Cancer 2022; 152:661-671. [PMID: 36056571 PMCID: PMC9538813 DOI: 10.1002/ijc.34273] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2022] [Revised: 07/19/2022] [Accepted: 08/18/2022] [Indexed: 02/01/2023]
Abstract
Previous studies on the immunogenicity of SARS-CoV-2 mRNA vaccines showed a reduced seroconversion in cancer patients. The aim of our study is to evaluate the immunogenicity of two doses of mRNA vaccines in solid cancer patients with or without a previous exposure to the virus. This is a single-institution, prospective, nonrandomized study. Patients in active treatment and a control cohort of healthy people received two doses of BNT162b2 (Comirnaty, BioNTech/Pfizer, The United States) or mRNA-1273 (Spikevax, Moderna). Vaccine was administered before starting anticancer therapy or on the first day of the treatment cycle. SARS-CoV-2 antibody levels against S1, RBD (to evaluate vaccine response) and N proteins (to evaluate previous infection) were measured in plasma before the first dose and 30 days after the second one. From January to June 2021, 195 consecutive cancer patients and 20 healthy controls were enrolled. Thirty-one cancer patients had a previous exposure to SARS-CoV-2. Cancer patients previously exposed to the virus had significantly higher median levels of anti-S1 and anti-RBD IgG, compared to healthy controls (P = .0349) and to cancer patients without a previous infection (P < .001). Vaccine type (anti-S1: P < .0001; anti-RBD: P = .0045), comorbidities (anti-S1: P = .0274; anti-RBD: P = .0048) and the use of G-CSF (anti-S1: P = .0151) negatively affected the antibody response. Conversely, previous exposure to SARS-CoV-2 significantly enhanced the response to vaccination (anti-S1: P < .0001; anti-RBD: P = .0026). Vaccine immunogenicity in cancer patients with a previous exposure to SARS-CoV-2 seems comparable to that of healthy subjects. On the other hand, clinical variables of immune frailty negatively affect humoral immune response to vaccination.
Collapse
Affiliation(s)
- Nicla La Verde
- Department of OncologySacco Hospital, ASST Fatebenefratelli SaccoMilanItaly
| | - Agostino Riva
- Department of Infectious DiseasesSacco Hospital, ASST Fatebenefratelli SaccoMilanItaly,Luigi Sacco Department of Biomedical and Clinical Sciences DIBICUniversity of MilanMilanItaly
| | - Maria Silvia Cona
- Department of OncologySacco Hospital, ASST Fatebenefratelli SaccoMilanItaly
| | - Arianna Gabrieli
- Luigi Sacco Department of Biomedical and Clinical Sciences DIBICUniversity of MilanMilanItaly
| | - Monica Cattaneo
- Department of OncologySacco Hospital, ASST Fatebenefratelli SaccoMilanItaly
| | - Cinzia Fasola
- Department of OncologySacco Hospital, ASST Fatebenefratelli SaccoMilanItaly
| | - Giuseppe Lipari
- Luigi Sacco Department of Biomedical and Clinical Sciences DIBICUniversity of MilanMilanItaly
| | - Claudia De Stradis
- Luigi Sacco Department of Biomedical and Clinical Sciences DIBICUniversity of MilanMilanItaly
| | - Valentina Favorito
- Department of OncologySacco Hospital, ASST Fatebenefratelli SaccoMilanItaly
| | | | - Davide Chizzoniti
- Department of OncologySacco Hospital, ASST Fatebenefratelli SaccoMilanItaly
| | - Alice Covizzi
- Department of Infectious DiseasesSacco Hospital, ASST Fatebenefratelli SaccoMilanItaly
| | - Eliana Rulli
- Laboratory of Methodology for Clinical ResearchIstituto di Ricerche Farmacologiche Mario Negri IRCCSMilanItaly
| | - Francesca Galli
- Laboratory of Methodology for Clinical ResearchIstituto di Ricerche Farmacologiche Mario Negri IRCCSMilanItaly
| | - Lorenzo Ruggieri
- Department of OncologySacco Hospital, ASST Fatebenefratelli SaccoMilanItaly
| | - Anna Gambaro
- Department of OncologySacco Hospital, ASST Fatebenefratelli SaccoMilanItaly
| | - Sabrina Ferrario
- Department of OncologySacco Hospital, ASST Fatebenefratelli SaccoMilanItaly
| | - Davide Dalu
- Department of OncologySacco Hospital, ASST Fatebenefratelli SaccoMilanItaly
| | - Maciej S. Tarkowski
- Luigi Sacco Department of Biomedical and Clinical Sciences DIBICUniversity of MilanMilanItaly
| |
Collapse
|
7
|
Pathak GA, Karjalainen J, Stevens C, Neale BM, Daly M, Ganna A, Andrews SJ, Kanai M, Cordioli M, Polimanti R, Harerimana N, Pirinen M, Liao RG, Chwialkowska K, Trankiem A, Balaconis MK, Nguyen H, Solomonson M, Veerapen K, Wolford B, Roberts G, Park D, Ball CA, Coignet M, McCurdy S, Knight S, Partha R, Rhead B, Zhang M, Berkowitz N, Gaddis M, Noto K, Ruiz L, Pavlovic M, Hong EL, Rand K, Girshick A, Guturu H, Baltzell AH, Niemi MEK, Rahmouni S, Guntz J, Beguin Y, Cordioli M, Pigazzini S, Nkambule L, Georges M, Moutschen M, Misset B, Darcis G, Guiot J, Azarzar S, Gofflot S, Claassen S, Malaise O, Huynen P, Meuris C, Thys M, Jacques J, Léonard P, Frippiat F, Giot JB, Sauvage AS, Frenckell CV, Belhaj Y, Lambermont B, Nakanishi T, Morrison DR, Mooser V, Richards JB, Butler-Laporte G, Forgetta V, Li R, Ghosh B, Laurent L, Belisle A, Henry D, Abdullah T, Adeleye O, Mamlouk N, Kimchi N, Afrasiabi Z, Rezk N, Vulesevic B, Bouab M, Guzman C, Petitjean L, Tselios C, Xue X, Afilalo J, Afilalo M, Oliveira M, Brenner B, Brassard N, Durand M, Schurr E, Lepage P, Ragoussis J, Auld D, Chassé M, Kaufmann DE, Lathrop GM, Adra D, Hayward C, Glessner JT, Shaw DM, Campbell A, Morris M, Hakonarson H, Porteous DJ, Below J, Richmond A, Chang X, Polikowski H, Lauren PE, Chen HH, Wanying Z, Fawns-Ritchie C, North K, McCormick JB, Chang X, Glessner JR, Hakonarson H, Gignoux CR, Wicks SJ, Crooks K, Barnes KC, Daya M, Shortt J, Rafaels N, Chavan S, Timmers PRHJ, Wilson JF, Tenesa A, Kerr SM, D’Mellow K, Shahin D, El-Sherbiny YM, von Hohenstaufen KA, Sobh A, Eltoukhy MM, Nkambul L, Elhadidy TA, Abd Elghafar MS, El-Jawhari JJ, Mohamed AAS, Elnagdy MH, Samir A, Abdel-Aziz M, Khafaga WT, El-Lawaty WM, Torky MS, El-shanshory MR, Yassen AM, Hegazy MAF, Okasha K, Eid MA, Moahmed HS, Medina-Gomez C, Ikram MA, Uitterlinden AG, Mägi R, Milani L, Metspalu A, Laisk T, Läll K, Lepamets M, Esko T, Reimann E, Naaber P, Laane E, Pesukova J, Peterson P, Kisand K, Tabri J, Allos R, Hensen K, Starkopf J, Ringmets I, Tamm A, Kallaste A, Alavere H, Metsalu K, Puusepp M, Batini C, Tobin MD, Venn LD, Lee PH, Shrine N, Williams AT, Guyatt AL, John C, Packer RJ, Ali A, Free RC, Wang X, Wain LV, Hollox EJ, Bee CE, Adams EL, Palotie A, Ripatti S, Ruotsalainen S, Kristiansson K, Koskelainen S, Perola M, Donner K, Kivinen K, Palotie A, Kaunisto M, Rivolta C, Bochud PY, Bibert S, Boillat N, Nussle SG, Albrich W, Quinodoz M, Kamdar D, Suh N, Neofytos D, Erard V, Voide C, Bochud PY, Rivolta C, Bibert S, Quinodoz M, Kamdar D, Neofytos D, Erard V, Voide C, Friolet R, Vollenweider P, Pagani JL, Oddo M, zu Bentrup FM, Conen A, Clerc O, Marchetti O, Guillet A, Guyat-Jacques C, Foucras S, Rime M, Chassot J, Jaquet M, Viollet RM, Lannepoudenx Y, Portopena L, Bochud PY, Vollenweider P, Pagani JL, Desgranges F, Filippidis P, Guéry B, Haefliger D, Kampouri EE, Manuel O, Munting A, Papadimitriou-Olivgeris M, Regina J, Rochat-Stettler L, Suttels V, Tadini E, Tschopp J, Van Singer M, Viala B, Boillat-Blanco N, Brahier T, Hügli O, Meuwly JY, Pantet O, Gonseth Nussle S, Bochud M, D’Acremont V, Estoppey Younes S, Albrich WC, Suh N, Cerny A, O’Mahony L, von Mering C, Bochud PY, Frischknecht M, Kleger GR, Filipovic M, Kahlert CR, Wozniak H, Negro TR, Pugin J, Bouras K, Knapp C, Egger T, Perret A, Montillier P, di Bartolomeo C, Barda B, de Cid R, Carreras A, Moreno V, Kogevinas M, Galván-Femenía I, Blay N, Farré X, Sumoy L, Cortés B, Mercader JM, Guindo-Martinez M, Torrents D, Garcia-Aymerich J, Castaño-Vinyals G, Dobaño C, Gori M, Renieri A, Mari F, Mondelli MU, Castelli F, Vaghi M, Rusconi S, Montagnani F, Bargagli E, Franchi F, Mazzei MA, Cantarini L, Tacconi D, Feri M, Scala R, Spargi G, Nencioni C, Bandini M, Caldarelli GP, Canaccini A, Ognibene A, D’Arminio Monforte A, Girardis M, Antinori A, Francisci D, Schiaroli E, Scotton PG, Panese S, Scaggiante R, Monica MD, Capasso M, Fiorentino G, Castori M, Aucella F, Biagio AD, Masucci L, Valente S, Mandalà M, Zucchi P, Giannattasio F, Coviello DA, Mussini C, Tavecchia L, Crotti L, Rizzi M, Rovere MTL, Sarzi-Braga S, Bussotti M, Ravaglia S, Artuso R, Perrella A, Romani D, Bergomi P, Catena E, Vincenti A, Ferri C, Grassi D, Pessina G, Tumbarello M, Pietro MD, Sabrina R, Luchi S, Furini S, Dei S, Benetti E, Picchiotti N, Sanarico M, Ceri S, Pinoli P, Raimondi F, Biscarini F, Stella A, Zguro K, Capitani K, Nkambule L, Tanfoni M, Fallerini C, Daga S, Baldassarri M, Fava F, Frullanti E, Valentino F, Doddato G, Giliberti A, Tita R, Amitrano S, Bruttini M, Croci S, Meloni I, Mencarelli MA, Rizzo CL, Pinto AM, Beligni G, Tommasi A, Sarno LD, Palmieri M, Carriero ML, Alaverdian D, Busani S, Bruno R, Vecchia M, Belli MA, Mantovani S, Ludovisi S, Quiros-Roldan E, Antoni MD, Zanella I, Siano M, Emiliozzi A, Fabbiani M, Rossetti B, Bergantini L, D’Alessandro M, Cameli P, Bennett D, Anedda F, Marcantonio S, Scolletta S, Guerrini S, Conticini E, Frediani B, Spertilli C, Donati A, Guidelli L, Corridi M, Croci L, Piacentini P, Desanctis E, Cappelli S, Verzuri A, Anemoli V, Pancrazzi A, Lorubbio M, Miraglia FG, Venturelli S, Cossarizza A, Vergori A, Gabrieli A, Riva A, Paciosi F, Andretta F, Gatti F, Parisi SG, Baratti S, Piscopo C, Russo R, Andolfo I, Iolascon A, Carella M, Merla G, Squeo GM, Raggi P, Marciano C, Perna R, Bassetti M, Sanguinetti M, Giorli A, Salerni L, Parravicini P, Menatti E, Trotta T, Coiro G, Lena F, Martinelli E, Mancarella S, Gabbi C, Maggiolo F, Ripamonti D, Bachetti T, Suardi C, Parati G, Bottà G, Domenico PD, Rancan I, Bianchi F, Colombo R, Barbieri C, Acquilini D, Andreucci E, Segala FV, Tiseo G, Falcone M, Lista M, Poscente M, Vivo OD, Petrocelli P, Guarnaccia A, Baroni S, Hayward C, Porteous DJ, Fawns-Ritchie C, Richmond A, Campbell A, van Heel DA, Hunt KA, Trembath RC, Huang QQ, Martin HC, Mason D, Trivedi B, Wright J, Finer S, Akhtar S, Anwar M, Arciero E, Ashraf S, Breen G, Chung R, Curtis CJ, Chowdhury M, Colligan G, Deloukas P, Durham C, Finer S, Griffiths C, Huang QQ, Hurles M, Hunt KA, Hussain S, Islam K, Khan A, Khan A, Lavery C, Lee SH, Lerner R, MacArthur D, MacLaughlin B, Martin H, Mason D, Miah S, Newman B, Safa N, Tahmasebi F, Trembath RC, Trivedi B, van Heel DA, Wright J, Griffiths CJ, Smith AV, Boughton AP, Li KW, LeFaive J, Annis A, Niavarani A, Aliannejad R, Sharififard B, Amirsavadkouhi A, Naderpour Z, Tadi HA, Aleagha AE, Ahmadi S, Moghaddam SBM, Adamsara A, Saeedi M, Abdollahi H, Hosseini A, Chariyavilaskul P, Jantarabenjakul W, Hirankarn N, Chamnanphon M, Suttichet TB, Shotelersuk V, Pongpanich M, Phokaew C, Chetruengchai W, Putchareon O, Torvorapanit P, Puthanakit T, Suchartlikitwong P, Nilaratanakul V, Sodsai P, Brumpton BM, Hveem K, Willer C, Wolford B, Zhou W, Rogne T, Solligard E, Åsvold BO, Franke L, Boezen M, Deelen P, Claringbould A, Lopera E, Warmerdam R, Vonk JM, van Blokland I, Lanting P, Ori APS, Feng YCA, Mercader J, Weiss ST, Karlson EW, Smoller JW, Murphy SN, Meigs JB, Woolley AE, Green RC, Perez EF, Wolford B, Zöllner S, Wang J, Beck A, Sloofman LG, Ascolillo S, Sebra RP, Collins BL, Levy T, Buxbaum JD, Sealfon SC, Jordan DM, Thompson RC, Gettler K, Chaudhary K, Belbin GM, Preuss M, Hoggart C, Choi S, Underwood SJ, Salib I, Britvan B, Keller K, Tang L, Peruggia M, Hiester LL, Niblo K, Aksentijevich A, Labkowsky A, Karp A, Zlatopolsky M, Zyndorf M, Charney AW, Beckmann ND, Schadt EE, Abul-Husn NS, Cho JH, Itan Y, Kenny EE, Loos RJF, Nadkarni GN, Do R, O’Reilly P, Huckins LM, Ferreira MAR, Abecasis GR, Leader JB, Cantor MN, Justice AE, Carey DJ, Chittoor G, Josyula NS, Kosmicki JA, Horowitz JE, Baras A, Gass MC, Yadav A, Mirshahi T, Hottenga JJ, Bartels M, de geus EEJC, Nivard MMG, Verma A, Ritchie MD, Rader D, Li B, Verma SS, Lucas A, Bradford Y, Abedalthagafi M, Alaamery M, Alshareef A, Sawaji M, Massadeh S, AlMalik A, Alqahtani S, Baraka D, Harthi FA, Alsolm E, Safieh LA, Alowayn AM, Alqubaishi F, Mutairi AA, Mangul S, Almutairi M, Aljawini N, Albesher N, Arabi YM, Mahmoud ES, Khattab AK, Halawani RT, Alahmadey ZZ, Albakri JK, Felemban WA, Suliman BA, Hasanato R, Al-Awdah L, Alghamdi J, AlZahrani D, AlJohani S, Al-Afghani H, AlDhawi N, AlBardis H, Alkwai S, Alswailm M, Almalki F, Albeladi M, Almohammed I, Barhoush E, Albader A, Alotaibi S, Alghamdi B, Jung J, fawzy MS, Alrashed M, Zeberg H, Nkambul L, Frithiof R, Hultström M, Lipcsey M, Tardif N, Rooyackers O, Grip J, Maricic T, Helgeland Ø, Magnus P, Trogstad LIS, Lee Y, Harris JR, Mangino M, Spector TD, Emma D, Moutsianas L, Caulfield MJ, Scott RH, Kousathanas A, Pasko D, Walker S, Stuckey A, Odhams CA, Rhodes D, Fowler T, Rendon A, Chan G, Arumugam P, Karczewski KJ, Martin AR, Wilson DJ, Spencer CCA, Crook DW, Wyllie DH, O’Connell AM, Atkinson EG, Kanai M, Tsuo K, Baya N, Turley P, Gupta R, Walters RK, Palmer DS, Sarma G, Solomonson M, Cheng N, Lu W, Churchhouse C, Goldstein JI, King D, Zhou W, Seed C, Daly MJ, Neale BM, Finucane H, Bryant S, Satterstrom FK, Band G, Earle SG, Lin SK, Arning N, Koelling N, Armstrong J, Rudkin JK, Callier S, Bryant S, Cusick C, Soranzo N, Zhao JH, Danesh J, Angelantonio ED, Butterworth AS, Sun YV, Huffman JE, Cho K, O’Donnell CJ, Tsao P, Gaziano JM, Peloso G, Ho YL, Smieszek SP, Polymeropoulos C, Polymeropoulos V, Polymeropoulos MH, Przychodzen BP, Fernandez-Cadenas I, Planas AM, Perez-Tur J, Llucià-Carol L, Cullell N, Muiño E, Cárcel-Márquez J, DeDiego ML, Iglesias LL, Soriano A, Rico V, Agüero D, Bedini JL, Lozano F, Domingo C, Robles V, Ruiz-Jaén F, Márquez L, Gomez J, Coto E, Albaiceta GM, García-Clemente M, Dalmau D, Arranz MJ, Dietl B, Serra-Llovich A, Soler P, Colobrán R, Martín-Nalda A, Martínez AP, Bernardo D, Rojo S, Fiz-López A, Arribas E, de la Cal-Sabater P, Segura T, González-Villa E, Serrano-Heras G, Martí-Fàbregas J, Jiménez-Xarrié E, de Felipe Mimbrera A, Masjuan J, García-Madrona S, Domínguez-Mayoral A, Villalonga JM, Menéndez-Valladares P, Chasman DI, Sesso HD, Manson JE, Buring JE, Ridker PM, Franco G, Davis L, Lee S, Priest J, Sankaran VG, van Heel D, Biesecker L, Kerchberger VE, Baillie JK. A first update on mapping the human genetic architecture of COVID-19. Nature 2022; 608:E1-E10. [PMID: 35922517 PMCID: PMC9352569 DOI: 10.1038/s41586-022-04826-7] [Citation(s) in RCA: 52] [Impact Index Per Article: 26.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2021] [Accepted: 04/29/2022] [Indexed: 01/04/2023]
|
8
|
Rusconi S, Saladini F, Bellocchi MC, Galli L, Gagliardini R, Gazzola L, Francisci D, Vichi F, Focà E, Zazzi M, Santoro MM, Gabrieli A, Castagna A. Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects. Pharmacol Res 2022; 176:106064. [PMID: 34999223 DOI: 10.1016/j.phrs.2022.106064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/01/2021] [Revised: 01/04/2022] [Accepted: 01/04/2022] [Indexed: 11/17/2022]
Affiliation(s)
| | | | | | - Laura Galli
- San Raffaele Vita-Salute University, Milan, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Tarkowski M, de Jager W, Schiuma M, Covizzi A, Lai A, Gabrieli A, Corbellino M, Bergna A, Ventura CD, Galli M, Riva A, Antinori S. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History. Front Immunol 2021; 12:793191. [PMID: 34975897 PMCID: PMC8718396 DOI: 10.3389/fimmu.2021.793191] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2021] [Accepted: 11/30/2021] [Indexed: 11/13/2022] Open
Abstract
Purpose To compare SARS-CoV-2 antigen-specific antibody production and plasma neutralizing capacity against B.1 wild-type-like strain, and Gamma/P.1 and Delta/B.1.617.2 variants-of-concern, in subjects with different Covid-19 disease and vaccination histories. Methods Adult subjects were: 1) Unvaccinated/hospitalized for Covid-19; 2) Covid-19-recovered followed by one BNT162b2 vaccine dose; and 3) Covid-19-naïve/2-dose BNT162b2 vaccinated. Multiplex Luminex® immunoassays measured IgG, IgA, and IgM plasma levels against SARS-CoV-2 receptor-binding domain (RBD), spike-1 (S), and nucleocapsid proteins. Neutralizing activity was determined in Vero E6 cytopathic assays. Results Maximum anti-RBD IgG levels were similar in Covid-19‑recovered individuals 8‒10 days after single-dose vaccination and in Covid-19-naïve subjects 7 days after 2nd vaccine dosing; both groups had ≈2‑fold higher anti-RBD IgG levels than Unvaccinated/Covid-19 subjects tracked through 2 weeks post-symptom onset. Anti-S IgG expression patterns were similar to RBD within each group, but with lower signal strengths. Viral antigen-specific IgA and IgM levels were more variable than IgG patterns. Anti-nucleocapsid immunoglobulins were not detected in Covid-19-naïve subjects. Neutralizing activity against the B.1 strain, and Gamma/P.1 and Delta/B.1.617.2 variants, was highest in Covid‑19-recovered/single-dose vaccinated subjects; although neutralization against the Delta variant in this group was only 26% compared to B.1 neutralization, absolute anti-Delta titers suggested maintained protection. Neutralizing titers against the Gamma and Delta variants were 33‒77% and 26‒67%, respectively, versus neutralization against the B.1 strain (100%) in the three groups. Conclusion These findings support SARS-CoV-2 mRNA vaccine usefulness regardless of Covid-19 history, and confirm remarkable protection provided by a single vaccine dose in people who have recovered from Covid-19.
Collapse
Affiliation(s)
- Maciej Tarkowski
- Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy
| | | | - Marco Schiuma
- Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy
| | - Alice Covizzi
- Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy
| | - Alessia Lai
- Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy
| | - Arianna Gabrieli
- Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy
| | - Mario Corbellino
- Division of Infectious Diseases, Aziende Socio Sanitarie Territoriali (ASST) Fatebenefratelli Sacco Hospital, Milan, Italy
| | - Annalisa Bergna
- Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy
| | - Carla Della Ventura
- Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy
| | - Massimo Galli
- Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy
| | - Agostino Riva
- Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy
| | - Spinello Antinori
- Department of Biomedical and Clinical Sciences L. Sacco, Università degli Studi di Milano, Milan, Italy
| |
Collapse
|
10
|
Milazzo L, Pezzati L, Oreni L, Kullmann C, Lai A, Gabrieli A, Bestetti G, Beschi C, Conti F, Ottomano C, Gervasoni C, Meroni L, Galli M, Antinori S, Ridolfo AL. Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy. Hum Vaccin Immunother 2021; 17:4747-4754. [PMID: 35086438 PMCID: PMC8862160 DOI: 10.1080/21645515.2021.2002639] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Revised: 10/13/2021] [Accepted: 11/02/2021] [Indexed: 02/06/2023] Open
Abstract
In Italy, SARS-CoV-2 vaccination campaign prioritized healthcare workers (HCWs) to receive two doses of BNT162b2 vaccine, irrespective of a previous SARS-CoV-2 infection. In this real-life study, we compared the humoral response to BNT162b2 vaccine in HCWs with and without a previous SARS-CoV-2 infection. Of the 407 HCWs enrolled, 334 (82.1%) were SARS-CoV-2-naive and 73 (17.9%) SARS-CoV-2-experienced. Post-vaccine humoral response was detectable in more than 98% of HCWs. Overall, the median level of anti-S IgG in SARS-COV-2-experienced HCWs was twice as high as those of SARS-CoV-2-naive subjects (24641.0 AU/mL [IQR: 15273.0->40000.0] versus 13053.8 [IQR: 7303.3-20105.8]; p < .001), irrespective of the time elapsed from SARS-CoV-2 previous infection. In a subgroup of SARS-CoV-2-naive and -experienced subjects who received only one dose of the vaccine, the latter showed 32 times higher levels of anti-S IgG compared to the former. Although no serious adverse events have been reported, mild to moderate side effects occurred more frequently after the first dose in the SARS-CoV-2-experienced than in naive subjects (67% versus 42%, respectively; p < .001). Notably, post-vaccination anti-SARS-CoV-2 spike IgG levels ≥20,000 AU/mL were independently associated with the risk of fever ≥38°C (adjusted odds ratio [aOR] 5.122, 95% CI 2.368-11.080, p < .0001).Our study showed high responsiveness of BNT162b2 vaccine and a relationship between levels of antibody response and reactogenicity. It suggests that a single dose of mRNA vaccine might evoke effective protection in SARS-CoV-2-experienced subjects.
Collapse
Affiliation(s)
- Laura Milazzo
- Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Laura Pezzati
- Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Letizia Oreni
- Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy
| | | | - Alessia Lai
- Luigi Sacco Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
| | - Arianna Gabrieli
- Luigi Sacco Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
| | - Giovanna Bestetti
- Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy
| | | | - Federico Conti
- Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy
| | | | - Cristina Gervasoni
- Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Luca Meroni
- Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy
| | - Massimo Galli
- Luigi Sacco Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
| | - Spinello Antinori
- Luigi Sacco Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy
| | - Anna Lisa Ridolfo
- Department of Infectious Diseases, ASST Fatebenefratelli Sacco, Milan, Italy
| |
Collapse
|
11
|
Tortorici MA, Beltramello M, Lempp FA, Pinto D, Dang HV, Rosen LE, McCallum M, Bowen J, Minola A, Jaconi S, Zatta F, De Marco A, Guarino B, Bianchi S, Lauron EJ, Tucker H, Zhou J, Peter A, Havenar-Daughton C, Wojcechowskyj JA, Case JB, Chen RE, Kaiser H, Montiel-Ruiz M, Meury M, Czudnochowski N, Spreafico R, Dillen J, Ng C, Sprugasci N, Culap K, Benigni F, Abdelnabi R, Foo SYC, Schmid MA, Cameroni E, Riva A, Gabrieli A, Galli M, Pizzuto MS, Neyts J, Diamond MS, Virgin HW, Snell G, Corti D, Fink K, Veesler D. Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science 2020; 370:950-957. [PMID: 32972994 PMCID: PMC7857395 DOI: 10.1126/science.abe3354] [Citation(s) in RCA: 408] [Impact Index Per Article: 102.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2020] [Accepted: 09/21/2020] [Indexed: 12/29/2022]
Abstract
Efficient therapeutic options are needed to control the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has caused more than 922,000 fatalities as of 13 September 2020. We report the isolation and characterization of two ultrapotent SARS-CoV-2 human neutralizing antibodies (S2E12 and S2M11) that protect hamsters against SARS-CoV-2 challenge. Cryo-electron microscopy structures show that S2E12 and S2M11 competitively block angiotensin-converting enzyme 2 (ACE2) attachment and that S2M11 also locks the spike in a closed conformation by recognition of a quaternary epitope spanning two adjacent receptor-binding domains. Antibody cocktails that include S2M11, S2E12, or the previously identified S309 antibody broadly neutralize a panel of circulating SARS-CoV-2 isolates and activate effector functions. Our results pave the way to implement antibody cocktails for prophylaxis or therapy, circumventing or limiting the emergence of viral escape mutants.
Collapse
MESH Headings
- Amino Acid Motifs/immunology
- Angiotensin-Converting Enzyme 2
- Animals
- Antibodies, Neutralizing/administration & dosage
- Antibodies, Neutralizing/immunology
- Antibodies, Neutralizing/isolation & purification
- Antibodies, Viral/administration & dosage
- Antibodies, Viral/immunology
- Antibodies, Viral/isolation & purification
- Betacoronavirus/immunology
- CHO Cells
- COVID-19
- Coronavirus Infections/prevention & control
- Coronavirus Infections/therapy
- Cricetinae
- Cricetulus
- Cryoelectron Microscopy
- HEK293 Cells
- Humans
- Immunodominant Epitopes/chemistry
- Immunodominant Epitopes/immunology
- Microscopy, Electron
- Pandemics/prevention & control
- Peptidyl-Dipeptidase A/immunology
- Pneumonia, Viral/prevention & control
- Pneumonia, Viral/therapy
- Protein Domains/immunology
- SARS-CoV-2
- Spike Glycoprotein, Coronavirus/antagonists & inhibitors
- Spike Glycoprotein, Coronavirus/chemistry
- Spike Glycoprotein, Coronavirus/immunology
Collapse
Affiliation(s)
- M Alejandra Tortorici
- Department of Biochemistry, University of Washington, Seattle, WA 98195, USA
- Institut Pasteur and CNRS UMR 3569, Unité de Virologie Structurale, Paris, France
| | - Martina Beltramello
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
| | | | - Dora Pinto
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
| | - Ha V Dang
- Department of Biochemistry, University of Washington, Seattle, WA 98195, USA
| | | | - Matthew McCallum
- Department of Biochemistry, University of Washington, Seattle, WA 98195, USA
| | - John Bowen
- Department of Biochemistry, University of Washington, Seattle, WA 98195, USA
| | - Andrea Minola
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
| | - Stefano Jaconi
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
| | - Fabrizia Zatta
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
| | - Anna De Marco
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
| | - Barbara Guarino
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
| | - Siro Bianchi
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
| | | | | | - Jiayi Zhou
- Vir Biotechnology, San Francisco, CA 94158, USA
| | - Alessia Peter
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
| | | | | | - James Brett Case
- Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA
| | - Rita E Chen
- Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA
| | | | | | | | | | | | - Josh Dillen
- Vir Biotechnology, San Francisco, CA 94158, USA
| | - Cindy Ng
- Vir Biotechnology, San Francisco, CA 94158, USA
| | - Nicole Sprugasci
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
| | - Katja Culap
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
| | - Fabio Benigni
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
| | - Rana Abdelnabi
- Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium
| | - Shi-Yan Caroline Foo
- Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium
| | - Michael A Schmid
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
| | - Elisabetta Cameroni
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
| | - Agostino Riva
- III Division of Infectious Diseases, Luigi Sacco University Hospital, University of Milan, Italy
| | - Arianna Gabrieli
- III Division of Infectious Diseases, Luigi Sacco University Hospital, University of Milan, Italy
| | - Massimo Galli
- III Division of Infectious Diseases, Luigi Sacco University Hospital, University of Milan, Italy
| | - Matteo S Pizzuto
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
| | - Johan Neyts
- Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, KU Leuven, Belgium
| | - Michael S Diamond
- Departments of Medicine, Molecular Microbiology, Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA
| | - Herbert W Virgin
- Vir Biotechnology, San Francisco, CA 94158, USA
- Washington University School of Medicine, St. Louis, MO, USA
- UTSouthwestern Medical Center, Dallas, TX, USA
| | | | - Davide Corti
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland
| | - Katja Fink
- Humabs BioMed SA, a subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
| | - David Veesler
- Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.
| |
Collapse
|
12
|
Zehender G, Lai A, Bergna A, Meroni L, Riva A, Balotta C, Tarkowski M, Gabrieli A, Bernacchia D, Rusconi S, Rizzardini G, Antinori S, Galli M. Genomic characterization and phylogenetic analysis of SARS-COV-2 in Italy. J Med Virol 2020; 92:1637-1640. [PMID: 32222993 PMCID: PMC7228393 DOI: 10.1002/jmv.25794] [Citation(s) in RCA: 103] [Impact Index Per Article: 25.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2020] [Revised: 03/23/2020] [Accepted: 03/24/2020] [Indexed: 12/02/2022]
Abstract
This report describes the isolation, molecular characterization, and phylogenetic analysis of the first three complete genomes of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) isolated from three patients involved in the first outbreak of COVID‐19 in Lombardy, Italy. Early molecular epidemiological tracing suggests that SARS‐CoV‐2 was present in Italy weeks before the first reported cases of infection.
Collapse
Affiliation(s)
- Gianguglielmo Zehender
- Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.,EpiSoMi CRC-Coordinated Research Center, University of Milan, Milan, Italy.,Romeo ed Enrica Invernizzi Pediatric Research Center, University of Milan, Milan, Italy
| | - Alessia Lai
- Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.,EpiSoMi CRC-Coordinated Research Center, University of Milan, Milan, Italy
| | - Annalisa Bergna
- Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy
| | - Luca Meroni
- III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy
| | - Agostino Riva
- III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy
| | - Claudia Balotta
- Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy
| | - Maciej Tarkowski
- Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy
| | - Arianna Gabrieli
- Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy
| | - Dario Bernacchia
- III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy
| | - Stefano Rusconi
- Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.,III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy
| | | | - Spinello Antinori
- Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.,III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy
| | - Massimo Galli
- Department of Biomedical and Clinical Sciences Luigi Sacco, University of Milan, Milan, Italy.,EpiSoMi CRC-Coordinated Research Center, University of Milan, Milan, Italy.,III Division of Infectious Diseases, ASST Fatebenefratelli Sacco, Luigi Sacco Hospital, Milan, Italy
| |
Collapse
|
13
|
Agnes P, Albuquerque IFM, Alexander T, Alton AK, Araujo GR, Asner DM, Ave M, Back HO, Baldin B, Batignani G, Biery K, Bocci V, Bonfini G, Bonivento W, Bottino B, Budano F, Bussino S, Cadeddu M, Cadoni M, Calaprice F, Caminata A, Canci N, Candela A, Caravati M, Cariello M, Carlini M, Carpinelli M, Catalanotti S, Cataudella V, Cavalcante P, Cavuoti S, Cereseto R, Chepurnov A, Cicalò C, Cifarelli L, Cocco AG, Covone G, D'Angelo D, D'Incecco M, D'Urso D, Davini S, De Candia A, De Cecco S, De Deo M, De Filippis G, De Rosa G, De Vincenzi M, Demontis P, Derbin AV, Devoto A, Di Eusanio F, Di Pietro G, Dionisi C, Downing M, Edkins E, Empl A, Fan A, Fiorillo G, Fomenko K, Franco D, Gabriele F, Gabrieli A, Galbiati C, Garcia Abia P, Ghiano C, Giagu S, Giganti C, Giovanetti GK, Gorchakov O, Goretti AM, Granato F, Gromov M, Guan M, Guardincerri Y, Gulino M, Hackett BR, Hassanshahi MH, Herner K, Hosseini B, Hughes D, Humble P, Hungerford EV, Ianni A, Ianni A, Ippolito V, James I, Johnson TN, Kahn Y, Keeter K, Kendziora CL, Kochanek I, Koh G, Korablev D, Korga G, Kubankin A, Kuss M, La Commara M, Lai M, Li X, Lisanti M, Lissia M, Loer B, Longo G, Ma Y, Machado AA, Machulin IN, Mandarano A, Mapelli L, Mari SM, Maricic J, Martoff CJ, Messina A, Meyers PD, Milincic R, Mishra-Sharma S, Monte A, Morrocchi M, Mount BJ, Muratova VN, Musico P, Nania R, Navrer Agasson A, Nozdrina AO, Oleinik A, Orsini M, Ortica F, Pagani L, Pallavicini M, Pandola L, Pantic E, Paoloni E, Pazzona F, Pelczar K, Pelliccia N, Pesudo V, Picciau E, Pocar A, Pordes S, Poudel SS, Pugachev DA, Qian H, Ragusa F, Razeti M, Razeto A, Reinhold B, Renshaw AL, Rescigno M, Riffard Q, Romani A, Rossi B, Rossi N, Sablone D, Samoylov O, Sands W, Sanfilippo S, Sant M, Santorelli R, Savarese C, Scapparone E, Schlitzer B, Segreto E, Semenov DA, Shchagin A, Sheshukov A, Singh PN, Skorokhvatov MD, Smirnov O, Sotnikov A, Stanford C, Stracka S, Suffritti GB, Suvorov Y, Tartaglia R, Testera G, Tonazzo A, Trinchese P, Unzhakov EV, Verducci M, Vishneva A, Vogelaar B, Wada M, Waldrop TJ, Wang H, Wang Y, Watson AW, Westerdale S, Wojcik MM, Wojcik M, Xiang X, Xiao X, Yang C, Ye Z, Zhu C, Zichichi A, Zuzel G. Constraints on Sub-GeV Dark-Matter-Electron Scattering from the DarkSide-50 Experiment. Phys Rev Lett 2018; 121:111303. [PMID: 30265123 DOI: 10.1103/physrevlett.121.111303] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Revised: 07/16/2018] [Indexed: 06/08/2023]
Abstract
We present new constraints on sub-GeV dark-matter particles scattering off electrons based on 6780.0 kg d of data collected with the DarkSide-50 dual-phase argon time projection chamber. This analysis uses electroluminescence signals due to ionized electrons extracted from the liquid argon target. The detector has a very high trigger probability for these signals, allowing for an analysis threshold of three extracted electrons, or approximately 0.05 keVee. We calculate the expected recoil spectra for dark matter-electron scattering in argon and, under the assumption of momentum-independent scattering, improve upon existing limits from XENON10 for dark-matter particles with masses between 30 and 100 MeV/c^{2}.
Collapse
Affiliation(s)
- P Agnes
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - I F M Albuquerque
- Instituto de Física, Universidade de São Paulo, São Paulo 05508-090, Brazil
| | - T Alexander
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - A K Alton
- Physics Department, Augustana University, Sioux Falls, South Dakota 57197, USA
| | - G R Araujo
- Instituto de Física, Universidade de São Paulo, São Paulo 05508-090, Brazil
| | - D M Asner
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - M Ave
- Instituto de Física, Universidade de São Paulo, São Paulo 05508-090, Brazil
| | - H O Back
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - B Baldin
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - G Batignani
- INFN Pisa, Pisa 56127, Italy
- Physics Department, Università degli Studi di Pisa, Pisa 56127, Italy
| | - K Biery
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - V Bocci
- INFN Sezione di Roma, Roma 00185, Italy
| | - G Bonfini
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | | | - B Bottino
- Physics Department, Università degli Studi di Genova, Genova 16146, Italy
- INFN Genova, Genova 16146, Italy
| | - F Budano
- INFN Roma Tre, Roma 00146, Italy
- Mathematics and Physics Department, Università degli Studi Roma Tre, Roma 00146, Italy
| | - S Bussino
- INFN Roma Tre, Roma 00146, Italy
- Mathematics and Physics Department, Università degli Studi Roma Tre, Roma 00146, Italy
| | - M Cadeddu
- INFN Cagliari, Cagliari 09042, Italy
- Physics Department, Università degli Studi di Cagliari, Cagliari 09042, Italy
| | - M Cadoni
- INFN Cagliari, Cagliari 09042, Italy
- Physics Department, Università degli Studi di Cagliari, Cagliari 09042, Italy
| | - F Calaprice
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | | | - N Canci
- Department of Physics, University of Houston, Houston, Texas 77204, USA
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - A Candela
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - M Caravati
- INFN Cagliari, Cagliari 09042, Italy
- Physics Department, Università degli Studi di Cagliari, Cagliari 09042, Italy
| | | | - M Carlini
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - M Carpinelli
- Chemistry and Pharmacy Department, Università degli Studi di Sassari, Sassari 07100, Italy
- INFN Laboratori Nazionali del Sud, Catania 95123, Italy
| | - S Catalanotti
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
| | - V Cataudella
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
| | - P Cavalcante
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
- Virginia Tech, Blacksburg, Virginia 24061, USA
| | - S Cavuoti
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
| | | | - A Chepurnov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, Moscow 119234, Russia
| | - C Cicalò
- INFN Cagliari, Cagliari 09042, Italy
| | - L Cifarelli
- Physics Department, Università degli Studi di Bologna, Bologna 40126, Italy
- INFN Bologna, Bologna 40126, Italy
| | | | - G Covone
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
| | - D D'Angelo
- Physics Department, Università degli Studi di Milano, Milano 20133, Italy
- INFN Milano, Milano 20133, Italy
| | - M D'Incecco
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - D D'Urso
- Chemistry and Pharmacy Department, Università degli Studi di Sassari, Sassari 07100, Italy
- INFN Laboratori Nazionali del Sud, Catania 95123, Italy
| | - S Davini
- INFN Genova, Genova 16146, Italy
| | - A De Candia
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
| | - S De Cecco
- INFN Sezione di Roma, Roma 00185, Italy
- Physics Department, Sapienza Università di Roma, Roma 00185, Italy
| | - M De Deo
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - G De Filippis
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
| | - G De Rosa
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
| | - M De Vincenzi
- INFN Roma Tre, Roma 00146, Italy
- Mathematics and Physics Department, Università degli Studi Roma Tre, Roma 00146, Italy
| | - P Demontis
- Chemistry and Pharmacy Department, Università degli Studi di Sassari, Sassari 07100, Italy
- INFN Laboratori Nazionali del Sud, Catania 95123, Italy
- Interuniversity Consortium for Science and Technology of Materials, Firenze 50121, Italy
| | - A V Derbin
- Saint Petersburg Nuclear Physics Institute, Gatchina 188350, Russia
| | - A Devoto
- INFN Cagliari, Cagliari 09042, Italy
- Physics Department, Università degli Studi di Cagliari, Cagliari 09042, Italy
| | - F Di Eusanio
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - G Di Pietro
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
- INFN Milano, Milano 20133, Italy
| | - C Dionisi
- INFN Sezione di Roma, Roma 00185, Italy
- Physics Department, Sapienza Università di Roma, Roma 00185, Italy
| | - M Downing
- Amherst Center for Fundamental Interactions and Physics Department, University of Massachusetts, Amherst, Massachusetts 01003, USA
| | - E Edkins
- Department of Physics and Astronomy, University of Hawai'i, Honolulu, Hawai'i 96822, USA
| | - A Empl
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - A Fan
- Physics and Astronomy Department, University of California, Los Angeles, California 90095, USA
| | - G Fiorillo
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
| | - K Fomenko
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - D Franco
- APC, Université Paris Diderot, CNRS/IN2P3, CEA/Irfu, Obs de Paris, USPC, Paris 75205, France
| | - F Gabriele
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - A Gabrieli
- Chemistry and Pharmacy Department, Università degli Studi di Sassari, Sassari 07100, Italy
- INFN Laboratori Nazionali del Sud, Catania 95123, Italy
| | - C Galbiati
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
- Gran Sasso Science Institute, L'Aquila 67100, Italy
| | - P Garcia Abia
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid 28040, Spain
| | - C Ghiano
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - S Giagu
- INFN Sezione di Roma, Roma 00185, Italy
- Physics Department, Sapienza Università di Roma, Roma 00185, Italy
| | - C Giganti
- LPNHE, CNRS/IN2P3, Sorbonne Université, Université Paris Diderot, Paris 75252, France
| | - G K Giovanetti
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - O Gorchakov
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - A M Goretti
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - F Granato
- Physics Department, Temple University, Philadelphia, Pennsylvania 19122, USA
| | - M Gromov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, Moscow 119234, Russia
| | - M Guan
- Institute of High Energy Physics, Beijing 100049, China
| | - Y Guardincerri
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - M Gulino
- INFN Laboratori Nazionali del Sud, Catania 95123, Italy
- Engineering and Architecture Faculty, Università di Enna Kore, Enna 94100, Italy
| | - B R Hackett
- Department of Physics and Astronomy, University of Hawai'i, Honolulu, Hawai'i 96822, USA
| | - M H Hassanshahi
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - K Herner
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | | | - D Hughes
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - P Humble
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - E V Hungerford
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - Al Ianni
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - An Ianni
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | | | - I James
- INFN Roma Tre, Roma 00146, Italy
- Mathematics and Physics Department, Università degli Studi Roma Tre, Roma 00146, Italy
| | - T N Johnson
- Department of Physics, University of California, Davis, California 95616, USA
| | - Y Kahn
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - K Keeter
- School of Natural Sciences, Black Hills State University, Spearfish, South Dakota 57799, USA
| | - C L Kendziora
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - I Kochanek
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - G Koh
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - D Korablev
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - G Korga
- Department of Physics, University of Houston, Houston, Texas 77204, USA
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - A Kubankin
- Radiation Physics Laboratory, Belgorod National Research University, Belgorod 308007, Russia
| | - M Kuss
- INFN Pisa, Pisa 56127, Italy
| | - M La Commara
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
| | - M Lai
- INFN Cagliari, Cagliari 09042, Italy
- Physics Department, Università degli Studi di Cagliari, Cagliari 09042, Italy
| | - X Li
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - M Lisanti
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - M Lissia
- INFN Cagliari, Cagliari 09042, Italy
| | - B Loer
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - G Longo
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
| | - Y Ma
- Institute of High Energy Physics, Beijing 100049, China
| | - A A Machado
- Physics Institute, Universidade Estadual de Campinas, Campinas 13083, Brazil
| | - I N Machulin
- National Research Centre Kurchatov Institute, Moscow 123182, Russia
- National Research Nuclear University MEPhI, Moscow 115409, Russia
| | - A Mandarano
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
- Gran Sasso Science Institute, L'Aquila 67100, Italy
| | - L Mapelli
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - S M Mari
- INFN Roma Tre, Roma 00146, Italy
- Mathematics and Physics Department, Università degli Studi Roma Tre, Roma 00146, Italy
| | - J Maricic
- Department of Physics and Astronomy, University of Hawai'i, Honolulu, Hawai'i 96822, USA
| | - C J Martoff
- Physics Department, Temple University, Philadelphia, Pennsylvania 19122, USA
| | - A Messina
- INFN Sezione di Roma, Roma 00185, Italy
- Physics Department, Sapienza Università di Roma, Roma 00185, Italy
| | - P D Meyers
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - R Milincic
- Department of Physics and Astronomy, University of Hawai'i, Honolulu, Hawai'i 96822, USA
| | - S Mishra-Sharma
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - A Monte
- Amherst Center for Fundamental Interactions and Physics Department, University of Massachusetts, Amherst, Massachusetts 01003, USA
| | | | - B J Mount
- School of Natural Sciences, Black Hills State University, Spearfish, South Dakota 57799, USA
| | - V N Muratova
- Saint Petersburg Nuclear Physics Institute, Gatchina 188350, Russia
| | - P Musico
- INFN Genova, Genova 16146, Italy
| | - R Nania
- INFN Bologna, Bologna 40126, Italy
| | - A Navrer Agasson
- LPNHE, CNRS/IN2P3, Sorbonne Université, Université Paris Diderot, Paris 75252, France
| | - A O Nozdrina
- National Research Centre Kurchatov Institute, Moscow 123182, Russia
- National Research Nuclear University MEPhI, Moscow 115409, Russia
| | - A Oleinik
- Radiation Physics Laboratory, Belgorod National Research University, Belgorod 308007, Russia
| | - M Orsini
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - F Ortica
- Chemistry, Biology and Biotechnology Department, Università degli Studi di Perugia, Perugia 06123, Italy
- INFN Perugia, Perugia 06123, Italy
| | - L Pagani
- Department of Physics, University of California, Davis, California 95616, USA
| | - M Pallavicini
- Physics Department, Università degli Studi di Genova, Genova 16146, Italy
- INFN Genova, Genova 16146, Italy
| | - L Pandola
- INFN Laboratori Nazionali del Sud, Catania 95123, Italy
| | - E Pantic
- Department of Physics, University of California, Davis, California 95616, USA
| | - E Paoloni
- INFN Pisa, Pisa 56127, Italy
- Physics Department, Università degli Studi di Pisa, Pisa 56127, Italy
| | - F Pazzona
- Chemistry and Pharmacy Department, Università degli Studi di Sassari, Sassari 07100, Italy
- INFN Laboratori Nazionali del Sud, Catania 95123, Italy
| | - K Pelczar
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - N Pelliccia
- Chemistry, Biology and Biotechnology Department, Università degli Studi di Perugia, Perugia 06123, Italy
- INFN Perugia, Perugia 06123, Italy
| | - V Pesudo
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid 28040, Spain
| | - E Picciau
- INFN Cagliari, Cagliari 09042, Italy
- Physics Department, Università degli Studi di Cagliari, Cagliari 09042, Italy
| | - A Pocar
- Amherst Center for Fundamental Interactions and Physics Department, University of Massachusetts, Amherst, Massachusetts 01003, USA
| | - S Pordes
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - S S Poudel
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - D A Pugachev
- National Research Centre Kurchatov Institute, Moscow 123182, Russia
| | - H Qian
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - F Ragusa
- Physics Department, Università degli Studi di Milano, Milano 20133, Italy
- INFN Milano, Milano 20133, Italy
| | - M Razeti
- INFN Cagliari, Cagliari 09042, Italy
| | - A Razeto
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - B Reinhold
- Department of Physics and Astronomy, University of Hawai'i, Honolulu, Hawai'i 96822, USA
| | - A L Renshaw
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | | | - Q Riffard
- APC, Université Paris Diderot, CNRS/IN2P3, CEA/Irfu, Obs de Paris, USPC, Paris 75205, France
| | - A Romani
- Chemistry, Biology and Biotechnology Department, Università degli Studi di Perugia, Perugia 06123, Italy
- INFN Perugia, Perugia 06123, Italy
| | - B Rossi
- INFN Napoli, Napoli 80126, Italy
| | - N Rossi
- INFN Sezione di Roma, Roma 00185, Italy
| | - D Sablone
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - O Samoylov
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - W Sands
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - S Sanfilippo
- INFN Roma Tre, Roma 00146, Italy
- Mathematics and Physics Department, Università degli Studi Roma Tre, Roma 00146, Italy
| | - M Sant
- Chemistry and Pharmacy Department, Università degli Studi di Sassari, Sassari 07100, Italy
- INFN Laboratori Nazionali del Sud, Catania 95123, Italy
| | - R Santorelli
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid 28040, Spain
| | - C Savarese
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
- Gran Sasso Science Institute, L'Aquila 67100, Italy
| | | | - B Schlitzer
- Department of Physics, University of California, Davis, California 95616, USA
| | - E Segreto
- Physics Institute, Universidade Estadual de Campinas, Campinas 13083, Brazil
| | - D A Semenov
- Saint Petersburg Nuclear Physics Institute, Gatchina 188350, Russia
| | - A Shchagin
- Radiation Physics Laboratory, Belgorod National Research University, Belgorod 308007, Russia
| | - A Sheshukov
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - P N Singh
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - M D Skorokhvatov
- National Research Centre Kurchatov Institute, Moscow 123182, Russia
- National Research Nuclear University MEPhI, Moscow 115409, Russia
| | - O Smirnov
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - A Sotnikov
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - C Stanford
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | | | - G B Suffritti
- Chemistry and Pharmacy Department, Università degli Studi di Sassari, Sassari 07100, Italy
- INFN Laboratori Nazionali del Sud, Catania 95123, Italy
- Interuniversity Consortium for Science and Technology of Materials, Firenze 50121, Italy
| | - Y Suvorov
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
- Physics and Astronomy Department, University of California, Los Angeles, California 90095, USA
- National Research Centre Kurchatov Institute, Moscow 123182, Russia
| | - R Tartaglia
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | | | - A Tonazzo
- APC, Université Paris Diderot, CNRS/IN2P3, CEA/Irfu, Obs de Paris, USPC, Paris 75205, France
| | - P Trinchese
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
| | - E V Unzhakov
- Saint Petersburg Nuclear Physics Institute, Gatchina 188350, Russia
| | - M Verducci
- INFN Sezione di Roma, Roma 00185, Italy
- Physics Department, Sapienza Università di Roma, Roma 00185, Italy
| | - A Vishneva
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - B Vogelaar
- Virginia Tech, Blacksburg, Virginia 24061, USA
| | - M Wada
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - T J Waldrop
- Physics Department, Augustana University, Sioux Falls, South Dakota 57197, USA
| | - H Wang
- Physics and Astronomy Department, University of California, Los Angeles, California 90095, USA
| | - Y Wang
- Physics and Astronomy Department, University of California, Los Angeles, California 90095, USA
| | - A W Watson
- Physics Department, Temple University, Philadelphia, Pennsylvania 19122, USA
| | - S Westerdale
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - M M Wojcik
- M. Smoluchowski Institute of Physics, Jagiellonian University, 30-348 Krakow, Poland
| | - M Wojcik
- Institute of Applied Radiation Chemistry, Lodz University of Technology, 93-590 Lodz, Poland
| | - X Xiang
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - X Xiao
- Physics and Astronomy Department, University of California, Los Angeles, California 90095, USA
| | - C Yang
- Institute of High Energy Physics, Beijing 100049, China
| | - Z Ye
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - C Zhu
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - A Zichichi
- Physics Department, Università degli Studi di Bologna, Bologna 40126, Italy
- INFN Bologna, Bologna 40126, Italy
| | - G Zuzel
- M. Smoluchowski Institute of Physics, Jagiellonian University, 30-348 Krakow, Poland
| |
Collapse
|
14
|
Agnes P, Albuquerque IFM, Alexander T, Alton AK, Araujo GR, Asner DM, Ave M, Back HO, Baldin B, Batignani G, Biery K, Bocci V, Bonfini G, Bonivento W, Bottino B, Budano F, Bussino S, Cadeddu M, Cadoni M, Calaprice F, Caminata A, Canci N, Candela A, Caravati M, Cariello M, Carlini M, Carpinelli M, Catalanotti S, Cataudella V, Cavalcante P, Cavuoti S, Cereseto R, Chepurnov A, Cicalò C, Cifarelli L, Cocco AG, Covone G, D'Angelo D, D'Incecco M, D'Urso D, Davini S, De Candia A, De Cecco S, De Deo M, De Filippis G, De Rosa G, De Vincenzi M, Demontis P, Derbin AV, Devoto A, Di Eusanio F, Di Pietro G, Dionisi C, Downing M, Edkins E, Empl A, Fan A, Fiorillo G, Fomenko K, Franco D, Gabriele F, Gabrieli A, Galbiati C, Garcia Abia P, Ghiano C, Giagu S, Giganti C, Giovanetti GK, Gorchakov O, Goretti AM, Granato F, Gromov M, Guan M, Guardincerri Y, Gulino M, Hackett BR, Hassanshahi MH, Herner K, Hosseini B, Hughes D, Humble P, Hungerford EV, Ianni A, Ianni A, Ippolito V, James I, Johnson TN, Kahn Y, Keeter K, Kendziora CL, Kochanek I, Koh G, Korablev D, Korga G, Kubankin A, Kuss M, La Commara M, Lai M, Li X, Lisanti M, Lissia M, Loer B, Longo G, Ma Y, Machado AA, Machulin IN, Mandarano A, Mapelli L, Mari SM, Maricic J, Martoff CJ, Messina A, Meyers PD, Milincic R, Mishra-Sharma S, Monte A, Morrocchi M, Mount BJ, Muratova VN, Musico P, Nania R, Navrer Agasson A, Nozdrina AO, Oleinik A, Orsini M, Ortica F, Pagani L, Pallavicini M, Pandola L, Pantic E, Paoloni E, Pazzona F, Pelczar K, Pelliccia N, Pesudo V, Pocar A, Pordes S, Poudel SS, Pugachev DA, Qian H, Ragusa F, Razeti M, Razeto A, Reinhold B, Renshaw AL, Rescigno M, Riffard Q, Romani A, Rossi B, Rossi N, Sablone D, Samoylov O, Sands W, Sanfilippo S, Sant M, Santorelli R, Savarese C, Scapparone E, Schlitzer B, Segreto E, Semenov DA, Shchagin A, Sheshukov A, Singh PN, Skorokhvatov MD, Smirnov O, Sotnikov A, Stanford C, Stracka S, Suffritti GB, Suvorov Y, Tartaglia R, Testera G, Tonazzo A, Trinchese P, Unzhakov EV, Verducci M, Vishneva A, Vogelaar B, Wada M, Waldrop TJ, Wang H, Wang Y, Watson AW, Westerdale S, Wojcik MM, Wojcik M, Xiang X, Xiao X, Yang C, Ye Z, Zhu C, Zichichi A, Zuzel G. Low-Mass Dark Matter Search with the DarkSide-50 Experiment. Phys Rev Lett 2018; 121:081307. [PMID: 30192596 DOI: 10.1103/physrevlett.121.081307] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/28/2018] [Indexed: 06/08/2023]
Abstract
We present the results of a search for dark matter weakly interacting massive particles (WIMPs) in the mass range below 20 GeV/c^{2} using a target of low-radioactivity argon with a 6786.0 kg d exposure. The data were obtained using the DarkSide-50 apparatus at Laboratori Nazionali del Gran Sasso. The analysis is based on the ionization signal, for which the DarkSide-50 time projection chamber is fully efficient at 0.1 keVee. The observed rate in the detector at 0.5 keVee is about 1.5 event/keVee/kg/d and is almost entirely accounted for by known background sources. We obtain a 90% C.L. exclusion limit above 1.8 GeV/c^{2} for the spin-independent cross section of dark matter WIMPs on nucleons, extending the exclusion region for dark matter below previous limits in the range 1.8-6 GeV/c^{2}.
Collapse
Affiliation(s)
- P Agnes
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - I F M Albuquerque
- Instituto de Física, Universidade de São Paulo, São Paulo 05508-090, Brazil
| | - T Alexander
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - A K Alton
- Physics Department, Augustana University, Sioux Falls, South Dakota 57197, USA
| | - G R Araujo
- Instituto de Física, Universidade de São Paulo, São Paulo 05508-090, Brazil
| | - D M Asner
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - M Ave
- Instituto de Física, Universidade de São Paulo, São Paulo 05508-090, Brazil
| | - H O Back
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - B Baldin
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - G Batignani
- INFN Pisa, Pisa 56127, Italy
- Physics Department, Università degli Studi di Pisa, Pisa 56127, Italy
| | - K Biery
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - V Bocci
- INFN Sezione di Roma, Roma 00185, Italy
| | - G Bonfini
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | | | - B Bottino
- Physics Department, Università degli Studi di Genova, Genova 16146, Italy
- INFN Genova, Genova 16146, Italy
| | - F Budano
- INFN Roma Tre, Roma 00146, Italy
- Mathematics and Physics Department, Università degli Studi Roma Tre, Roma 00146, Italy
| | - S Bussino
- INFN Roma Tre, Roma 00146, Italy
- Mathematics and Physics Department, Università degli Studi Roma Tre, Roma 00146, Italy
| | - M Cadeddu
- INFN Cagliari, Cagliari 09042, Italy
- Physics Department, Università degli Studi di Cagliari, Cagliari 09042, Italy
| | - M Cadoni
- INFN Cagliari, Cagliari 09042, Italy
- Physics Department, Università degli Studi di Cagliari, Cagliari 09042, Italy
| | - F Calaprice
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | | | - N Canci
- Department of Physics, University of Houston, Houston, Texas 77204, USA
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - A Candela
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - M Caravati
- INFN Cagliari, Cagliari 09042, Italy
- Physics Department, Università degli Studi di Cagliari, Cagliari 09042, Italy
| | | | - M Carlini
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - M Carpinelli
- Chemistry and Pharmacy Department, Università degli Studi di Sassari, Sassari 07100, Italy
- INFN Laboratori Nazionali del Sud, Catania 95123, Italy
| | - S Catalanotti
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
| | - V Cataudella
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
| | - P Cavalcante
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
- Virginia Tech, Blacksburg, Virginia 24061, USA
| | - S Cavuoti
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
| | | | - A Chepurnov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, Moscow 119234, Russia
| | - C Cicalò
- INFN Cagliari, Cagliari 09042, Italy
| | - L Cifarelli
- Physics Department, Università degli Studi di Bologna, Bologna 40126, Italy
- INFN Bologna, Bologna 40126, Italy
| | | | - G Covone
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
| | - D D'Angelo
- Physics Department, Università degli Studi di Milano, Milano 20133, Italy
- INFN Milano, Milano 20133, Italy
| | - M D'Incecco
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - D D'Urso
- Chemistry and Pharmacy Department, Università degli Studi di Sassari, Sassari 07100, Italy
- INFN Laboratori Nazionali del Sud, Catania 95123, Italy
| | - S Davini
- INFN Genova, Genova 16146, Italy
| | - A De Candia
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
| | - S De Cecco
- INFN Sezione di Roma, Roma 00185, Italy
- Physics Department, Sapienza Università di Roma, Roma 00185, Italy
| | - M De Deo
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - G De Filippis
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
| | - G De Rosa
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
| | - M De Vincenzi
- INFN Roma Tre, Roma 00146, Italy
- Mathematics and Physics Department, Università degli Studi Roma Tre, Roma 00146, Italy
| | - P Demontis
- Chemistry and Pharmacy Department, Università degli Studi di Sassari, Sassari 07100, Italy
- INFN Laboratori Nazionali del Sud, Catania 95123, Italy
- Interuniversity Consortium for Science and Technology of Materials, Firenze 50121, Italy
| | - A V Derbin
- Saint Petersburg Nuclear Physics Institute, Gatchina 188350, Russia
| | - A Devoto
- INFN Cagliari, Cagliari 09042, Italy
- Physics Department, Università degli Studi di Cagliari, Cagliari 09042, Italy
| | - F Di Eusanio
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - G Di Pietro
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
- INFN Milano, Milano 20133, Italy
| | - C Dionisi
- INFN Sezione di Roma, Roma 00185, Italy
- Physics Department, Sapienza Università di Roma, Roma 00185, Italy
| | - M Downing
- Amherst Center for Fundamental Interactions and Physics Department, University of Massachusetts, Amherst, Massachusetts 01003, USA
| | - E Edkins
- Department of Physics and Astronomy, University of Hawai'i, Honolulu, Hawaii 96822, USA
| | - A Empl
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - A Fan
- Physics and Astronomy Department, University of California, Los Angeles, California 90095, USA
| | - G Fiorillo
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
| | - K Fomenko
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - D Franco
- APC, Université Paris Diderot, CNRS/IN2P3, CEA/Irfu, Obs de Paris, USPC, Paris 75205, France
| | - F Gabriele
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - A Gabrieli
- Chemistry and Pharmacy Department, Università degli Studi di Sassari, Sassari 07100, Italy
- INFN Laboratori Nazionali del Sud, Catania 95123, Italy
| | - C Galbiati
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
- Gran Sasso Science Institute, L'Aquila 67100, Italy
| | - P Garcia Abia
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid 28040, Spain
| | - Chiara Ghiano
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - S Giagu
- INFN Sezione di Roma, Roma 00185, Italy
- Physics Department, Sapienza Università di Roma, Roma 00185, Italy
| | - C Giganti
- LPNHE, CNRS/IN2P3, Sorbonne Université, Université Paris Diderot, Paris 75252, France
| | - G K Giovanetti
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - O Gorchakov
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - A M Goretti
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - F Granato
- Physics Department, Temple University, Philadelphia, Pennsylvania 19122, USA
| | - M Gromov
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, Moscow 119234, Russia
| | - M Guan
- Institute of High Energy Physics, Beijing 100049, China
| | - Y Guardincerri
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - M Gulino
- INFN Laboratori Nazionali del Sud, Catania 95123, Italy
- Engineering and Architecture Faculty, Università di Enna Kore, Enna 94100, Italy
| | - B R Hackett
- Department of Physics and Astronomy, University of Hawai'i, Honolulu, Hawaii 96822, USA
| | - M H Hassanshahi
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - K Herner
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | | | - D Hughes
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - P Humble
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - E V Hungerford
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - Al Ianni
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - An Ianni
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | | | - I James
- INFN Roma Tre, Roma 00146, Italy
- Mathematics and Physics Department, Università degli Studi Roma Tre, Roma 00146, Italy
| | - T N Johnson
- Department of Physics, University of California, Davis, California 95616, USA
| | - Y Kahn
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - K Keeter
- School of Natural Sciences, Black Hills State University, Spearfish, South Dakota 57799, USA
| | - C L Kendziora
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - I Kochanek
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - G Koh
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - D Korablev
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - G Korga
- Department of Physics, University of Houston, Houston, Texas 77204, USA
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - A Kubankin
- Radiation Physics Laboratory, Belgorod National Research University, Belgorod 308007, Russia
| | - M Kuss
- INFN Pisa, Pisa 56127, Italy
| | - M La Commara
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
| | - M Lai
- INFN Cagliari, Cagliari 09042, Italy
- Physics Department, Università degli Studi di Cagliari, Cagliari 09042, Italy
| | - X Li
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - M Lisanti
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - M Lissia
- INFN Cagliari, Cagliari 09042, Italy
| | - B Loer
- Pacific Northwest National Laboratory, Richland, Washington 99352, USA
| | - G Longo
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
| | - Y Ma
- Institute of High Energy Physics, Beijing 100049, China
| | - A A Machado
- Physics Institute, Universidade Estadual de Campinas, Campinas 13083, Brazil
| | - I N Machulin
- National Research Centre Kurchatov Institute, Moscow 123182, Russia
- National Research Nuclear University MEPhI, Moscow 115409, Russia
| | - A Mandarano
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
- Gran Sasso Science Institute, L'Aquila 67100, Italy
| | - L Mapelli
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - S M Mari
- INFN Roma Tre, Roma 00146, Italy
- Mathematics and Physics Department, Università degli Studi Roma Tre, Roma 00146, Italy
| | - J Maricic
- Department of Physics and Astronomy, University of Hawai'i, Honolulu, Hawaii 96822, USA
| | - C J Martoff
- Physics Department, Temple University, Philadelphia, Pennsylvania 19122, USA
| | - A Messina
- INFN Sezione di Roma, Roma 00185, Italy
- Physics Department, Sapienza Università di Roma, Roma 00185, Italy
| | - P D Meyers
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - R Milincic
- Department of Physics and Astronomy, University of Hawai'i, Honolulu, Hawaii 96822, USA
| | - S Mishra-Sharma
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - A Monte
- Amherst Center for Fundamental Interactions and Physics Department, University of Massachusetts, Amherst, Massachusetts 01003, USA
| | | | - B J Mount
- School of Natural Sciences, Black Hills State University, Spearfish, South Dakota 57799, USA
| | - V N Muratova
- Saint Petersburg Nuclear Physics Institute, Gatchina 188350, Russia
| | - P Musico
- INFN Genova, Genova 16146, Italy
| | - R Nania
- INFN Bologna, Bologna 40126, Italy
| | - A Navrer Agasson
- LPNHE, CNRS/IN2P3, Sorbonne Université, Université Paris Diderot, Paris 75252, France
| | - A O Nozdrina
- National Research Centre Kurchatov Institute, Moscow 123182, Russia
- National Research Nuclear University MEPhI, Moscow 115409, Russia
| | - A Oleinik
- Radiation Physics Laboratory, Belgorod National Research University, Belgorod 308007, Russia
| | - M Orsini
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - F Ortica
- Chemistry, Biology and Biotechnology Department, Università degli Studi di Perugia, Perugia 06123, Italy
- INFN Perugia, Perugia 06123, Italy
| | - L Pagani
- Department of Physics, University of California, Davis, California 95616, USA
| | - M Pallavicini
- Physics Department, Università degli Studi di Genova, Genova 16146, Italy
- INFN Genova, Genova 16146, Italy
| | - L Pandola
- INFN Laboratori Nazionali del Sud, Catania 95123, Italy
| | - E Pantic
- Department of Physics, University of California, Davis, California 95616, USA
| | - E Paoloni
- INFN Pisa, Pisa 56127, Italy
- Physics Department, Università degli Studi di Pisa, Pisa 56127, Italy
| | - F Pazzona
- Chemistry and Pharmacy Department, Università degli Studi di Sassari, Sassari 07100, Italy
- INFN Laboratori Nazionali del Sud, Catania 95123, Italy
| | - K Pelczar
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - N Pelliccia
- Chemistry, Biology and Biotechnology Department, Università degli Studi di Perugia, Perugia 06123, Italy
- INFN Perugia, Perugia 06123, Italy
| | - V Pesudo
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid 28040, Spain
| | - A Pocar
- Amherst Center for Fundamental Interactions and Physics Department, University of Massachusetts, Amherst, Massachusetts 01003, USA
| | - S Pordes
- Fermi National Accelerator Laboratory, Batavia, Illinois 60510, USA
| | - S S Poudel
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - D A Pugachev
- National Research Centre Kurchatov Institute, Moscow 123182, Russia
| | - H Qian
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - F Ragusa
- Physics Department, Università degli Studi di Milano, Milano 20133, Italy
- INFN Milano, Milano 20133, Italy
| | - M Razeti
- INFN Cagliari, Cagliari 09042, Italy
| | - A Razeto
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | - B Reinhold
- Department of Physics and Astronomy, University of Hawai'i, Honolulu, Hawaii 96822, USA
| | - A L Renshaw
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | | | - Q Riffard
- APC, Université Paris Diderot, CNRS/IN2P3, CEA/Irfu, Obs de Paris, USPC, Paris 75205, France
| | - A Romani
- Chemistry, Biology and Biotechnology Department, Università degli Studi di Perugia, Perugia 06123, Italy
- INFN Perugia, Perugia 06123, Italy
| | - B Rossi
- INFN Napoli, Napoli 80126, Italy
| | - N Rossi
- INFN Sezione di Roma, Roma 00185, Italy
| | - D Sablone
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - O Samoylov
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - W Sands
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - S Sanfilippo
- INFN Roma Tre, Roma 00146, Italy
- Mathematics and Physics Department, Università degli Studi Roma Tre, Roma 00146, Italy
| | - M Sant
- Chemistry and Pharmacy Department, Università degli Studi di Sassari, Sassari 07100, Italy
- INFN Laboratori Nazionali del Sud, Catania 95123, Italy
| | - R Santorelli
- CIEMAT, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid 28040, Spain
| | - C Savarese
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
- Gran Sasso Science Institute, L'Aquila 67100, Italy
| | | | - B Schlitzer
- Department of Physics, University of California, Davis, California 95616, USA
| | - E Segreto
- Physics Institute, Universidade Estadual de Campinas, Campinas 13083, Brazil
| | - D A Semenov
- Saint Petersburg Nuclear Physics Institute, Gatchina 188350, Russia
| | - A Shchagin
- Radiation Physics Laboratory, Belgorod National Research University, Belgorod 308007, Russia
| | - A Sheshukov
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - P N Singh
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - M D Skorokhvatov
- National Research Centre Kurchatov Institute, Moscow 123182, Russia
- National Research Nuclear University MEPhI, Moscow 115409, Russia
| | - O Smirnov
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - A Sotnikov
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - C Stanford
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | | | - G B Suffritti
- Chemistry and Pharmacy Department, Università degli Studi di Sassari, Sassari 07100, Italy
- INFN Laboratori Nazionali del Sud, Catania 95123, Italy
- Interuniversity Consortium for Science and Technology of Materials, Firenze 50121, Italy
| | - Y Suvorov
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
- Physics and Astronomy Department, University of California, Los Angeles, California 90095, USA
- National Research Centre Kurchatov Institute, Moscow 123182, Russia
| | - R Tartaglia
- INFN Laboratori Nazionali del Gran Sasso, Assergi (AQ) 67100, Italy
| | | | - A Tonazzo
- APC, Université Paris Diderot, CNRS/IN2P3, CEA/Irfu, Obs de Paris, USPC, Paris 75205, France
| | - P Trinchese
- Physics Department, Università degli Studi "Federico II" di Napoli, Napoli 80126, Italy
- INFN Napoli, Napoli 80126, Italy
| | - E V Unzhakov
- Saint Petersburg Nuclear Physics Institute, Gatchina 188350, Russia
| | - M Verducci
- INFN Sezione di Roma, Roma 00185, Italy
- Physics Department, Sapienza Università di Roma, Roma 00185, Italy
| | - A Vishneva
- Joint Institute for Nuclear Research, Dubna 141980, Russia
| | - B Vogelaar
- Virginia Tech, Blacksburg, Virginia 24061, USA
| | - M Wada
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - T J Waldrop
- Physics Department, Augustana University, Sioux Falls, South Dakota 57197, USA
| | - H Wang
- Physics and Astronomy Department, University of California, Los Angeles, California 90095, USA
| | - Y Wang
- Physics and Astronomy Department, University of California, Los Angeles, California 90095, USA
| | - A W Watson
- Physics Department, Temple University, Philadelphia, Pennsylvania 19122, USA
| | - S Westerdale
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - M M Wojcik
- M. Smoluchowski Institute of Physics, Jagiellonian University, 30-348 Krakow, Poland
| | - M Wojcik
- Institute of Applied Radiation Chemistry, Lodz University of Technology, 93-590 Lodz, Poland
| | - X Xiang
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - X Xiao
- Physics and Astronomy Department, University of California, Los Angeles, California 90095, USA
| | - C Yang
- Institute of High Energy Physics, Beijing 100049, China
| | - Z Ye
- Department of Physics, University of Houston, Houston, Texas 77204, USA
| | - C Zhu
- Physics Department, Princeton University, Princeton, New Jersey 08544, USA
| | - A Zichichi
- Physics Department, Università degli Studi di Bologna, Bologna 40126, Italy
- INFN Bologna, Bologna 40126, Italy
| | - G Zuzel
- M. Smoluchowski Institute of Physics, Jagiellonian University, 30-348 Krakow, Poland
| |
Collapse
|
15
|
Drago L, De Vecchi E, Gabrieli A, De Grandi R, Toscano M. Immunomodulatory Effects of Lactobacillus salivarius LS01 and Bifidobacterium breve BR03, Alone and in Combination, on Peripheral Blood Mononuclear Cells of Allergic Asthmatics. Allergy Asthma Immunol Res 2015; 7:409-13. [PMID: 25749784 PMCID: PMC4446640 DOI: 10.4168/aair.2015.7.4.409] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/05/2014] [Revised: 12/15/2014] [Accepted: 01/02/2015] [Indexed: 12/13/2022]
Abstract
The aim of this study was to evaluate probiotic characteristics of Lactobacillus salivarius LS01 and Bifidobacterium breve BR03 alone and in combination and their immunomodulatory activity in asthmatic subjects. Subjects affected by allergic asthma were recruited. Initially, LS01 and BR03 were analyzed for their growth compatibility by a broth compatibility assay. To study the antimicrobial activity of probiotic strains, an agar diffusion assay was performed. Finally, cytokine production by peripheral blood mononuclear cells (PBMCs) stimulated with LS01 and BR03 was determined by means of specific quantitative enzyme-linked immunosorbent assay (ELISA). The growth of some clinical pathogens were slightly inhibited by LS01 and LS01-BR03 co-culture supernatant not neutralized to pH 6.5, while only the growth of E. coli and S. aureus was inhibited by the supernatant of LS01 and LS01-BR03 neutralized to pH 6.5. Furthermore, LS01 and BR03 combination was able to decrease the secretion of proinflammatory cytokines by PBMCs, leading to an intense increase in IL-10 production. L. salivarius LS01 and B. breve BR03 showed promising probiotic properties and beneficial immunomodulatory activity that are increased when the 2 strains are used in combination in the same formulation.
Collapse
Affiliation(s)
- Lorenzo Drago
- Laboratory of Technical Sciences for Laboratory Medicine, Department of Biomedical Science for Health, University of Milan, Milan, Italy.; Laboratory of Clinical Chemistry and Microbiology, IRCCS Galeazzi Orthopaedic Institute, Milan, Italy.
| | - Elena De Vecchi
- Laboratory of Clinical Chemistry and Microbiology, IRCCS Galeazzi Orthopaedic Institute, Milan, Italy
| | - Arianna Gabrieli
- Laboratory of Clinical Chemistry and Microbiology, IRCCS Galeazzi Orthopaedic Institute, Milan, Italy
| | - Roberta De Grandi
- Laboratory of Technical Sciences for Laboratory Medicine, Department of Biomedical Science for Health, University of Milan, Milan, Italy
| | - Marco Toscano
- Laboratory of Technical Sciences for Laboratory Medicine, Department of Biomedical Science for Health, University of Milan, Milan, Italy
| |
Collapse
|
16
|
Toscano M, De Vecchi E, Gabrieli A, Zuccotti GV, Drago L. Probiotic characteristics and in vitro compatibility of a combination of Bifidobacterium breve M-16 V, Bifidobacterium longum subsp. infantis M-63 and Bifidobacterium longum subsp. longum BB536. ANN MICROBIOL 2014. [DOI: 10.1007/s13213-014-0953-5] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023] Open
|
17
|
Penkov D, Mateos San Martín D, Fernandez-Díaz LC, Rosselló CA, Torroja C, Sánchez-Cabo F, Warnatz HJ, Sultan M, Yaspo ML, Gabrieli A, Tkachuk V, Brendolan A, Blasi F, Torres M. Analysis of the DNA-binding profile and function of TALE homeoproteins reveals their specialization and specific interactions with Hox genes/proteins. Cell Rep 2013; 3:1321-33. [PMID: 23602564 DOI: 10.1016/j.celrep.2013.03.029] [Citation(s) in RCA: 99] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2012] [Revised: 02/19/2013] [Accepted: 03/20/2013] [Indexed: 11/28/2022] Open
Abstract
The interactions of Meis, Prep, and Pbx1 TALE homeoproteins with Hox proteins are essential for development and disease. Although Meis and Prep behave similarly in vitro, their in vivo activities remain largely unexplored. We show that Prep and Meis interact with largely independent sets of genomic sites and select different DNA-binding sequences, Prep associating mostly with promoters and housekeeping genes and Meis with promoter-remote regions and developmental genes. Hox target sequences associate strongly with Meis but not with Prep binding sites, while Pbx1 cooperates with both Prep and Meis. Accordingly, Meis1 shows strong genetic interaction with Pbx1 but not with Prep1. Meis1 and Prep1 nonetheless coregulate a subset of genes, predominantly through opposing effects. Notably, the TALE homeoprotein binding profile subdivides Hox clusters into two domains differentially regulated by Meis1 and Prep1. During evolution, Meis and Prep thus specialized their interactions but maintained significant regulatory coordination.
Collapse
Affiliation(s)
- Dmitry Penkov
- Foundation FIRC Institute of Molecular Oncology at the IFOM-IEO Campus, via Adamello 16, 20139 Milan, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Mori S, Bernardi R, Laurent A, Resnati M, Crippa A, Gabrieli A, Keough R, Gonda TJ, Blasi F. Myb-binding protein 1A (MYBBP1A) is essential for early embryonic development, controls cell cycle and mitosis, and acts as a tumor suppressor. PLoS One 2012; 7:e39723. [PMID: 23056166 PMCID: PMC3466261 DOI: 10.1371/journal.pone.0039723] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2012] [Accepted: 05/25/2012] [Indexed: 11/24/2022] Open
Abstract
MYBBP1A is a predominantly nucleolar transcriptional regulator involved in rDNA synthesis and p53 activation via acetylation. However little further information is available as to its function. Here we report that MYBBP1A is developmentally essential in the mouse prior to blastocyst formation. In cell culture, down-regulation of MYBBP1A decreases the growth rate of wild type mouse embryonic stem cells, mouse embryo fibroblasts (MEFs) and of human HeLa cells, where it also promotes apoptosis. HeLa cells either arrest at G2/M or undergo delayed and anomalous mitosis. At mitosis, MYBBP1A is localized to a parachromosomal region and gene-expression profiling shows that its down-regulation affects genes controlling chromosomal segregation and cell cycle. However, MYBBP1A down-regulation increases the growth rate of the immortalized NIH3T3 cells. Such Mybbp1a down-regulated NIH3T3 cells are more susceptible to Ras-induced transformation and cause more potent Ras-driven tumors. We conclude that MYBBP1A is an essential gene with novel roles at the pre-mitotic level and potential tumor suppressor activity.
Collapse
Affiliation(s)
- Silvia Mori
- Università Vita Salute San Raffaele, Milan, Italy
| | - Rosa Bernardi
- Università Vita Salute San Raffaele, Milan, Italy
- San Raffaele Scientific Institute, Milan, Italy
| | - Audrey Laurent
- Fondazione Istituto FIRC di Oncologia Molecolare (IFOM), Milano, Italy
| | | | | | - Arianna Gabrieli
- Fondazione Istituto FIRC di Oncologia Molecolare (IFOM), Milano, Italy
| | - Rebecca Keough
- Flinders University, Bedford Park, Adelaide, South Australia, Australia
- Division of Human Immunology and Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
| | - Thomas J. Gonda
- University of Queensland Diamantina Institute, Brisbane, Queensland, Australia
- Division of Human Immunology and Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia
| | - Francesco Blasi
- Università Vita Salute San Raffaele, Milan, Italy
- Fondazione Istituto FIRC di Oncologia Molecolare (IFOM), Milano, Italy
- * E-mail:
| |
Collapse
|
19
|
Pazzona FG, Gabrieli A, Pintus AM, Demontis P, Suffritti GB. The central cell model: a mesoscopic hopping model for the study of the displacement autocorrelation function. J Chem Phys 2011; 134:184109. [PMID: 21568499 DOI: 10.1063/1.3587618] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
On the mesoscale, the molecular motion in a microporous material can be represented as a sequence of hops between different pore locations and from one pore to the other. On the same scale, the memory effects in the motion of a tagged particle are embedded in the displacement autocorrelation function (DACF), the discrete counterpart of the velocity autocorrelation function (VACF). In this paper, a mesoscopic hopping model, based on a lattice-gas automata dynamics, is presented for the coarse-grained modeling of the DACF in a microporous material under conditions of thermodynamic equilibrium. In our model, that we will refer to as central cell model, the motion of one tagged particle is mimicked through probabilistic hops from one location to the other in a small lattice of cells where all the other particles are indistinguishable; the cells closest to the one containing the tagged particle are simulated explicitly in the canonical ensemble, whereas the border cells are treated as mean-field cells in the grand-canonical ensemble. In the present paper, numerical simulation of the central cell model are shown to provide the same results as a traditional lattice-gas simulation. Along with this a mean-field theory of self-diffusion which incorporates time correlations is discussed.
Collapse
Affiliation(s)
- F G Pazzona
- Dipartimento di Chimica, Università degli Studi di Sassari and Consorzio Interuniversitario Nazionale per la Scienza e Tecnologia dei Materiali (INSTM), Unità di Ricerca di Sassari, Sassari, Italy.
| | | | | | | | | |
Collapse
|
20
|
Wild P, Gabrieli A, Schraner EM, Pellegrini A, Thomas U, Frederik PM, Stuart MC, Von Fellenberg R. Reevaluation of the effect of lysoyzme on Escherichia coli employing ultrarapid freezing followed by cryoelectronmicroscopy or freeze substitution. Microsc Res Tech 1997; 39:297-304. [PMID: 9372501 DOI: 10.1002/(sici)1097-0029(19971101)39:3<297::aid-jemt8>3.0.co;2-h] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Lysozyme is able to lyse Gram-positive bacteria acting as muramidase on the peptidoglycan polymer. Gram-negative bacteria in vitro are not lysed by lysozyme. It was assumed that the peptido-glycan is protected by the outer membrane and thus that Gram-negative bacteria are not affected by lysozyme without the aid of other factors such as EDTA or complement which enable lysozyme to penetrate the outer membrane. Accidentally, Pellegrini et al. [(1992) J. Appl. Bacteriol., 72:180-187] found that lysozyme per se is able to kill some Gram-negative bacteria. On the basis of morphological and immunocytochemical findings obtained from chemically fixed bacteria, it was concluded that lysozyme does not lyse Gram-negative bacteria but affects the cytoplasm of for example, Escherichia coli, leading to its disintegration, whilst the membranes do not break down. In an attempt to clarify the action of lysozyme on E. coli, we employed cryotechniques including ultrarapid freezing, cryomicroscopy and freeze substitution, and immunolabeling. Bacteria that were immediately frozen after exposure to lysozyme remained morphologically intact. Individual bacteria plated on agar after exposure to lysozyme were mostly intact when frozen within a few seconds. However, inner and outer membranes of 80% of the bacteria were disrupted, whereas the cytoplasm of only a few bacteria showed signs of disintegration when bacteria were frozen with a delay of only 5 min of plating onto pure agar or agar containing growth medium. After a period of time of 15 min between plating onto agar and freezing, about 97% of the bacteria showed changes of disintegration of various extent. Immunolabeling showed that lysozyme binds to the outer cell membrane and may penetrate the membrane, reaching the periplasmic space and possibly the inner cell membrane. The ultrastructural findings and the results of antibacterial assays suggest that lysozyme is bactericidal for E. coli but is not able to induce disintegration. Disintegration is accomplished by changes of the environment starting at the cell membranes. The mechanism by which lysozyme penetrates the membrane, the way it acts to be bactericidal, and the way disintegration is initiated remain to be clarified.
Collapse
Affiliation(s)
- P Wild
- Institute of Veterinary Anatomy, University of Zürich, Switzerland.
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Chiale PA, Przybylski J, Laiño RA, Halpern MS, Sánchez RA, Gabrieli A, Elizari MV, Rosenbaum MB. Electrocardiographic changes evoked by ajmaline in chronic Chagas' disease with manifest myocarditis. Am J Cardiol 1982; 49:14-20. [PMID: 6172031 DOI: 10.1016/0002-9149(82)90271-5] [Citation(s) in RCA: 38] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Conversion from Chagas' infection to chagasic myocarditis occurs slowly and the earliest signs of myocardial involvement are hard to define. To obtain new information on this difficult clinical problem, ajmaline was administered (1 mg/kg body weight intravenously) to 101 patients with Chagas' infection and to 46 patients without such infection (control group). In 3 patients in the control group left anterior hemiblock alone occurred whereas in the group with Chagas' infection, ajmaline caused the occurrence of right bundle branch block, left anterior hemiblock, or both, in 32 patients (31.6 percent), ventricular extrasystoles in 8 (7.9 percent) and ischemic ST-T changes in 7 (6.9 percent). Ajmaline may thus evoke the most typical electrocardiographic changes of chronic chagasic myocarditis in patients without signs of myocardial involvement or only minor nonspecific signs. A positive ajmaline test, defined in the present context as the occurrence of a fascicular block, ventricular arrhythmias or ischemic ST-T changes, may indicate the existence of localized areas of injured myocardial tissue, not enough to alter the electrocardiogram by itself, but able to give rise to severe abnormalities after exposure to the drug. The test may therefore be used as a nonspecific detector of myocardial damage, and thus may have a much broader scope of clinical application. In chronic Chagas' infection, the ajmaline test is a relatively simple and apparently safe procedure that may serve to unveil the earliest signs of chagasic myocarditis.
Collapse
|